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ABSTRACT
EVALUATION OF THE EFFECT OF CARVEDILOL ON THE THIOREDOXIN
PATHWAY IN H9C2 RAT CARDIOMYOCYTES
METAB ALHARBI
2019
The thioredoxin (Trx) system is an endogenous antioxidant system that affects
cell function and survival through controlling cellular redox status. Trx and TrxR are the
main enzymes in this system while thioredoxin interacting protein (TXNIP) is a negative
regulator. This study’s goal was to better understand the Trx system’s involvement in the
cardiovascular disease and modulate the pathway through drug treatment.
Carvedilol is a non-selective β-blocker that also exhibits antioxidant properties,
but the exact mechanism of the antioxidant effect is still unclear. H9c2 rat
cardiomyocytes were used to examine the effect of carvedilol on the Trx system under
normal conditions. Interestingly, carvedilol was able to decrease TXNIP not through its
expression or proteasomal degradation but through increased TXNIP nuclear localization.
Immunoprecipitation also showed an increase in TXNIP-PARP complexation in the
nucleus and a decrease in Trx-TXNIP complexation in the cytosol. The results indicate
that carvedilol may exhibit its antioxidant activity through altering TXNIP subcellular
localization.
TXNIP is known to be important in both physiologic and pathophysiologic
conditions. Western blot data showed that TXNIP in the cytosol will increase with
increasing glucose concentration. Oxidative stress inducers such as doxorubicin, hypoxiareoxygenation, and radiation were able to decrease cytosolic TXNIP.

xix
Doxorubicin is a commonly utilized anticancer drug that induces oxidative stress
and therefore causes cardiac toxicity. A study was conducted to determine if carvedilol
could protect against doxorubicin-induced cardiotoxicity through TXNIP modulation.
Carvedilol and doxorubicin alone reduced cytosolic TXNIP. Doxorubicin increased
mitochondrial translocation of TXNIP accompanied by the induction of apoptosis.
However, carvedilol was not able to prevent TXNIP mitochondrial translocation, but it
did protect against doxorubicin-induced apoptosis. The complex of Trx2 and the proapoptotic ASK1 in the mitochondria was increased with carvedilol pretreatment followed
by doxorubicin exposure. The increase in the ASK1-Trx2 complex can reduce apoptosis
through decreased ASK1 activation. This was confirmed through Western blot of cleaved
PARP. The findings are consistent with reports of TXNIP’s response to mild oxidative
stress conditions.
In conclusion, this study shows for the first time that carvedilol impacts TXNIP
localization and complexation and that the Trx pathway may be involved in carvedilol’s
observed cardioprotective effect.
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CHAPTER 1. INTRODUCTION AND BACKGROUND

1.1 Thiol Redox State
Thiol redox state (TRS) refers to the balance between reduced thiols and their
corresponding disulfides. In living cells, TRS plays an important role in several
biological processes including protein configuration, enzymatic function, and regulation
of transcription factor action.1
Thiols are organosulfur compounds characterized by a carbon-bonded sulfhydryl
(-SH) functional group. Both protein thiols and non-protein thiols are present in cells.
Protein thiols in the cell contain cysteine amino acid residues. Nonprotein thiols refer to
low molecular weight thiols such as glutathione (GSH). Thiols have a very important
antioxidant role in the biological system as a first line defense against free radicals and
reactive oxygen species (ROS). Thiols can be oxidized to disulfides upon encountering
free radicals or ROS. Some disulfide molecules are symmetric disulfides such as
glutathione disulfide (GSSG) which is formed between two identical thiol-containing
molecules. The mixed disulfides are formed between two different molecules, such as a
protein thiol and GSH. Thiols can also act as reducing agents for certain protein disulfide
bonds. The oxidized disulfides can be reduced back to their corresponding thiols by
enzymes such as glutathione reductase (GR), glutaredoxin (Grx), and thioredoxin
reductase (TrxR).2
The ratio between thiols and disulfides is used as an indicator of TRS. The normal
ratio of GSH to GSSG in whole cell lysates is approximately 100:1. However, the ratio of
thiols to disulfides varies by subcellular location; the GSH to GSSG ratio in the

2
endoplasmic reticulum can be as low as 1:1, for example. Thiol oxidative stress occurs
when the ratio of thiols to disulfides is lower than normal. This can occur due to
reductions in thiols and/or increases in the oxidized disulfides. Part of the cellular
response to oxidative stress is to increase thiol antioxidant capacity; for example,
induction of GSH synthesis occurs in response to oxidative stress.

1.2 Pathways Regulating Thiol Redox State
1.2.1 Thioredoxin
Thioredoxin (Trx) is an abundant antioxidant molecule that exists in multiple
species including humans, plants, fungi, and some bacteria and archaea. In 1964, the
initial Trx was found in E. coli, where it was acting as an electron donor for the
ribonucleotide reductase enzyme. Later, it became obvious that thioredoxin plays
essential roles in other cellular mechanisms.3 Trx can prevent or reduce ROS in the cell,
regulate programmed cell death by maintaining apoptosis signal-regulating kinase 1
(ASK1) activity, act as a growth factor, and regulate DNA synthesis.4, 5
Trx is a small molecular weight protein of ~12kDa.4 Human cells have three Trx
isoforms: Trx1 in the cytosol, Trx2 in mitochondria, and Trx3 in testis. All Trx proteins
have the same active catalytic motif of cysteine-glycine-proline-cysteine (Cys-Gly-ProCys). The cysteine residues of this motif are used to reduce disulfide bonds in oxidized
substrate proteins. This will result in a disulfide bond between the two cysteines which
will be reduced back via the thioredoxin reductase enzyme (TrxR) with the help of
nicotinamide adenine dinucleotide phosphate (NADPH) (Figure 1). The details of the Trx
catalyzed reduction of protein disulfides are provided below.
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The Trx catalytic reaction is a nucleophilic substitution reaction (SN2). The
reaction starts with a nucleophilic attack of the N-terminal cysteine of the Cys-Gly-ProCys motif on the disulfide. As a result of this step, there will be an intermediate disulfide
complex between Trx and the substrate. This intermediate complex will be reduced by a
nucleophilic attack by the C-terminal cysteine. This one catalytic reduction cycle will
give a reduced protein and oxidized Trx. Trx in its disulfide form is more stable than
reduced form. This alteration in stability between the disulfide and reduced forms of
thioredoxin is an important driving force for the reaction to occur. There are multiple
factors that affect the rate of the reduction reaction, such as the pKa of the cysteine, the
geometry of a linear transition-state, the electrostatic atmosphere of the surrounding
amino acids 6, 7, the pH of the solvent 8 and entropy.9
The Trx-fold can be found in multiple proteins and is highly evolutionarily
conserved. Trx catalyzed reduction of protein disulfides is critical for regulating of
activity of multiple enzymes and therefore is important for maintenance of cellular
homeostasis. Importantly, experiments with Trx knockout mice demonstrated that lack of
this protein is embryonically lethal.10

1.2.2 Thioredoxin Reductase
Thioredoxin reductase (TrxR) is a member of the pyridine nucleotide disulfide
oxidoreductase family, which is structurally different from other proteins as it includes a
unique amino acid called selenocysteine (Sec).11 Human TrxR is a 55kDa molecular
weight protein. The catalytic domain of TrxR includes a selenothiol bond between the
selenocysteine and the C-terminal cysteine.11 TrxR has three major isoforms: TrxR1 is
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cytosolic, TrxR2 is mitochondrial, and thioredoxin glutathione reductase (TGR) is testis
specific. All three isoforms contain a Sec residue.12 The main function of TrxR is to
maintain thioredoxins in a reduced state. Other proteins, such as Glutaredoxin 2 (Grx2)
and Protein Disulfide Isomerase (PDI), are also known to be reduced by TrxR.13, 14 It has
also been associated with multiple cellular signaling mechanisms and acts like a direct
antioxidant in the cell to maintain cellular redox homeostasis. Recently, inhibition of
TrxR has been suggested as a target for cancer treatment.15, 16

Figure 1. Redox cycle of thioredoxin

1.2.3 Thioredoxin-Interacting Protein
Thioredoxin-interacting protein (TXNIP), also known as vitamin D-upregulated
protein (VDUP1) or thioredoxin-binding-protein-2 (TBP2), works as a biological
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negative regulator for the Trx protein. TXNIP was initially cloned in the HL-60 leukemia
cell line treated with 1,25-dihydroxyvitamin D3.17 Since its initial discovery, TXNIP has
been identified as an important protein in both physiologic and pathophysiologic
conditions. Literature reports indicate that TXNIP is able to block the function and
activity of Trx. TXNIP can competitively bind to Trx and prevent it from binding to other
proteins such as ASK1.18 TXNIP can inhibit Trx via formation of a mixed disulfide bond
with the active site motif of reduced Trx (Figure 2). High expression of TXNIP can
reduce Trx activity in cases leading to an increase in protein oxidation in the cell. TXNIP
is a member of the α-arrestin superfamily of proteins and also exerts redox independent
functions such as its ability to act as a cell growth regulator, a tumor suppressor gene,
regulator of cell apoptosis, and modulator of the inflammatory response.10
TXNIP is a ubiquitously expressed redox protein and can localize between
cellular compartments, mainly the cytosol, nucleus and mitochondria.3, 19, 20 Under normal
conditions, TXNIP can be found in the cytosol and nucleus. Importin α is responsible for
transport of TXNIP into the nucleus. TXNIP shuttles to the mitochondria under oxidative
stress conditions. Beside TXNIP’s ability to bind to Trx1 in the cytosol, it can also bind
to poly (ADP-ribose) polymerase (PARP) in the nucleus. Under oxidative stress, TXNIP
will bind to Trx2 in the mitochondria, leading to decreased Trx2 binding to ASK1. This
will lead to ASK1 phosphorylation and activation, causing stimulation of the
mitochondrial pathways of apoptosis by both cytochrome c release and caspase-3
cleavage.21
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Figure 2. TXNIP-Trx Complexation
1.2.4 Glutathione
The tripeptide glutathione (GSH), γ-L-glutamyl-L-cysteinyl-glycine, is the most
ubiquitous thiol in biological systems. The GSH concentration is high in most tissues
(around 5 mM); however, the GSH concentration can vary in subcellular organelles. GSH
is synthesized in the cytosol by the action of the enzymes γ-glutamylcysteine synthase
(GCS) and glutathione synthase (GS). GSH serves a protective function in cells by acting
as an antioxidant and nucleophile. The oxidized form GSSG is reduced back to GSH by
the action of glutathione reductase (GR) (figure: 3).

Figure 3. Reduced glutathione (GSH) and oxidized glutathione (GSSG)
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1.3 Free Radicals and Oxidative Stress
Free radicals were discovered in the early 1900s by Moses Gomberg. It was
thought that free radicals were not present in biological systems until the 1950s, when
studies showed their existence and their role in disease pathogenesis and aging.22 Since
then, understanding of the effect of free radicals on living organisms has expanded
enormously. Free radicals were once thought to be only damaging species, but studies
have proven that they play a major role in biological systems under normal conditions.
Free radicals are atoms or molecules which have unpaired electron or electrons in
the outer orbital. Free radicals are unstable and highly reactive since they can attack other
molecules to obtain electrons to be stable.23 Molecules derived from oxygen are the most
important free radicals. Oxygen free radicals include superoxide (O2·-), hydroxyl (OH·),
and peroxyl radical (ROO·). The broader term reactive oxygen species (ROS) refers to
both radical and nonradical reactive forms of oxygen. For example, peroxides are
important nonradical ROS.
Normal cellular metabolism in living cells produces free radicals.24 Studies have
shown that most of the ROS are produced by the mitochondria respiratory chain and
subsequently produce toxic metabolic byproducts.25 Mitochondria produce ATP in which
oxygen (O2) is reduced to water. While mitochondrial respiration is occurring, the
electron transport chain will release electrons from the incompletely reduced O2 to form
superoxide. Manganese superoxide dismutase (Mn-SOD) will convert that to H2O2 in the
mitochondrial matrix.26 ROS generated in mitochondria can migrate to the cytoplasm
leading to oxidative damage to other cellular structures.27 NADPH oxidase and
cytochrome P450 contribute to ROS production for redox signaling and cell proliferation.
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A small amount of ROS is produced at the endoplasmic reticulum and nuclear membrane
which are mainly connected with the action of cytochrome P450 family enzymes.28, 29
Elimination of ROS is important to maintenance of cellular homeostasis.
Antioxidants are molecules that can quench damaging free radicals and ROS.
Antioxidants are divided into endogenous antioxidant systems and exogenously
administered antioxidants. The thiol redox state systems described above are major
endogenous antioxidant systems. Glutathione can directly quench ROS, or it can
indirectly act as an antioxidant by acting as a cofactor for detoxifying enzymes such as
glutathione peroxidase (GPX). The thioredoxin system acts as an antioxidant by
regulating the protein thiol-disulfide ratio. Other endogenous antioxidant systems include
superoxide dismutase (SOD) and catalase. Exogenous antioxidants primarily come from
food or supplement sources such as ascorbic acid (vitamins C), α-tocopherol (Vitamin E),
carotenoids, anthocyanins, and polyphenols.
The balance between the oxidation and elimination of ROS will result in a steady
state redox balance in living cells. This balance can be disrupted for multiple reasons
such as increased ROS production from endogenous or exogenous sources, decreased
production or intake of antioxidants, or inactivation of major antioxidant enzymes. When
one or more of these reasons occur, an imbalance occurs between ROS production and
elimination. This will result in oxidative stress where damage to the cell and disruption of
cellular functions can take place leading to several pathologies such as cardiovascular
disease, cancer, diabetes mellitus, and autoimmune disorders.30-32
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1.4 Oxidative Stress and Cardiovascular Disease
According to the World Health Organization's (WHO) global status report,
cardiovascular disorders (CVD) are the leading causes of death worldwide. CVD causes
17.9 million deaths per year, 31% of deaths globally. CVD costs hundreds of billions of
dollars globally, with expected costs of $1044 billion by 2030.33 CVD includes a variety
of cardiovascular conditions including heart failure, myocardial infarction, stroke,
arrhythmias, and heart valve diseases. There are well-known risk factors for CVD, for
instance diabetes, aging, obesity, tobacco smoking, family history, and oxidative stress.
Although CVD are multifactorial diseases, oxidative stress has been found in
several cardiovascular conditions. A direct cause and effect relationship between
oxidative stress and CVD has not been clearly elucidated. Some literature has
demonstrated specific damage to the cardiovascular system from oxidative stress leading
to disease development. On the other hand, it can be claimed that oxidative stress may be
a consequence of cardiovascular disease. Therefore, it may be associated with some
secondary effects of the disease process. This is still an unsettled question based on data
in the literature. A description of the effects of oxidative stress and thiol abnormalities in
specific cardiovascular disorders can be found below.

1.4.1 Heart Failure (HF)
Heart failure is a complicated clinical disorder that can result from any structural
or functional cardiac change that weakens the ability of the ventricle to work normally.
HF is a leading cause of morbidity and mortality and causes multiple complications such
as fluid retention, which also causes pulmonary congestion and peripheral edema, and
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low cardiac output.34 Extensive clinical and experimental studies over the past several
years have shown significant evidence that oxidative stress is enhanced and might be a
major player in HF.35 The increased production of ROS, mainly (O2·-), was observed in
patients with congestive heart failure. The same study also showed a significant decrease
in thiols such as GSH and SOD, as well as a decrease in vitamin C in those patients.36
Those findings have been correlated with increased severity of heart failure.
Numerous reports have shown that Trx1 prevents apoptosis, which has a crucial
role in the development of heart failure. Trx binds to the N-terminal region of ASK1
leading to decreased activation of ASK1 and inhibition of the ASK1-JNK-p38 apoptosis
pathway.21, 37 Furthermore, an in vivo study showed that overexpression of Trx1
prevented mitochondrial dysfunction and protected septic mice against heart failure.38
Serum Trx also has been used as a biomarker for heart failure severity. TrxR2 plays an
essential role in heart development and function. A study in TrxR2 knockout mice
showed morphological changes in the development of the cardiac cells leading to death in
a short time after birth.39 TrxR2 inactivation in aging mice lead to increased ROS
production and HIF-1 activation which led to mitochondrial damage and later cardiac
failure.40

1.4.2 Atherosclerosis
Oxidized low-density lipoprotein (LDL) uptake was shown to be one of the initial
causes of atherosclerosis.41 Oxidized LDL is more easily taken up by macrophages to
form foam cells, the initial step in fatty streak formation in atherosclerotic blood vessels.
Lipid lowering agents, such as lovastatin, can reduce LDL oxidation.42 Iron catalyzed
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free radical reactions may also be linked to development of atherosclerosis; an in vivo
study found that atherosclerotic lesions formed in an animal model has a significant
increase in iron content.43

1.4.3 Hypertension
Increased levels of (O2·-) and H2O2 have been reported with hypertension
patients.44 On the other hand, the levels of some antioxidants like GSH, vitamin D, and
SOD have been reported to be decreased in hypertensive patients.45, 46 Vitamin C
improved endothelial function by restoring the nitric oxide mediated vasodilation in
hypertensive patients.19 The renin-angiotensin system (RAAS) has been associated with
stimulating oxidative stress in vascular and endothelial smooth muscle cells, which might
be a significant mechanism for the etiology of hypertension.47
It should be noted that oxidative stress is not limited to hypertension, heart failure,
or atherosclerosis as the presence of ROS has also been documented in other
cardiovascular conditions such as diabetic cardiomyopathy and mitral regurgitation.
Since ROS are known to reduce heart function, it appears that cardiovascular
malfunctions seen in patients with different types of heart disease may be in part due to
oxidative stress.
Because of the role identified for oxidative stress in CVD, use of antioxidants in
treatment and prevention of CVD has been explored. Preclinical evidence suggested that
exogenous antioxidants could be effective in CVD treatment. However, clinical trial data
has been disappointing. To date, antioxidants have not shown beneficial effect in human
trials for CVD treatment. In fact, some trials have shown that antioxidant treatment
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contributed to negative outcomes. For example, vitamin E use in heart failure was not
only ineffective, but it also increased heart failure hospitalizations. Possible reasons for
this lack of clinical effect include pro-oxidant effects of small molecule antioxidants, the
multifactorial nature of CVD, and the contribution of nonradical oxidative modifications.

1.5 TXNIP in Cardiovascular Disease
TXNIP has a crucial role in cardiovascular and non-cardiovascular disorder
development due to its extensive physiological significance. The first study to examine
TXNIP’s effect on cardiomyocytes showed a significant decrease in the TXNIP gene
expression in response to exposing NRVM cells, a rat neonatal ventricular cell line, to
mechanical strain. In the same study, TXNIP was induced in the presence of ROS in a
dose-dependent manner leading to cardiomyocyte apoptosis.48 Another study showed that
TXNIP knockout mice were less susceptible to cardiac hypertrophy after a month of
pressure overload. However, this effect was lost after two months, and cardiac
remodeling was detected in those mice.49 This beneficial effect of TXNIP knockout was
observed due to metabolic changes as the mice showed higher glucose uptake in the
cardiomyocytes. In a different study, TXNIP was found to mediate Trx1 localization to
the nucleus leading to regulation of multiple transcription factors such as histone
deacetylase 4 (HDAC4), a negative regulator of cardiac hypertrophy.50 In vivo, knockout
of TXNIP improved cardiac function in a diabetic mouse model.10 In aging mice, TXNIP
mRNA expression and protein level were higher than normal in the aorta, while
decreasing TXNIP reduced mortality.51
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TXNIP was found to be upregulated in an in vivo model of myocardial ischemia
leading to apoptosis via ASK1 activation. TXNIP was also found to be involved in the
cardiac remodeling occurrence after cardiac ischemia. TXNIP reduction was found to
inhibit collagen synthesis and decrease myocardial scar tissue creation.18
TXNIP is connected very closely to lipid metabolism. Abnormalities in TXNIP
can lead to atherosclerosis and increase the chance of developing coronary artery disease.
HcB-19 mice, which have a mutation in the TXNIP gene leading to reduced expression,
exhibit increased insulin secretion, hypoglycemia, and hypertriglyceridemia in the fasting
state. It was hypothesized that this is due to abnormal cellular redox status caused by
TXNIP downregulation.40 On the other hand, TXNIP can cause atherosclerosis via
decreased thioredoxin activity and subsequently TNF-induced inflammation leading to
enhanced endothelial inflammation.18

1.6 TXNIP and Glucose Regulation
Numerous studies have demonstrated that TXNIP has a crucial role in hepatic
glucose production. TXNIP expression increases under hyperglycemic conditions, and it
has a critical role in the pathogenesis of diabetes. TXNIP has multiple metabolic effects
which cause or aggravate diabetes, such as controlling insulin sensitivity, inhibiting
glucose uptake in tissues, increasing production of glucose in the liver, and causing β-cell
dysfunction.
Intracellular abnormalities in HcB-19 mice and TXNIP knockout mouse models
have been well characterized.40, 49 TXNIP deficient mice undergo fasting hypoglycemia
and loss of glucagon activity. Compared to normal mice, the livers of TXNIP knockout
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mice produced significantly less glucose.49 These hepatocytes were not affected by
circulating hormones and other substrates. There was no effect in glycogen metabolism
and the activity of glucose-6-phosphatase (G6-P) which is the main enzyme in
gluconeogenesis. A different study showed that phosphoenolpyruvate carboxykinase
(PEPCK), which is also the main enzyme in the metabolic pathway of gluconeogenesis,
was unaffected in TXNIP knockout mice compared to normal mice.52 It's very well
known that one of the main functions of TXNIP is controlling the redox status in the
cellular system by influencing different molecules such as Trx and NADP/NADPH. This
observation connects to the impact of TXNIP expression on glucose level since cellular
redox status is documented to affect gluconeogenesis.53
In an in vivo study, TXNIP reduction improved insulin function and decreased
glucose level in diabetic mice.54 Another study showed that TXNIP knockout increased
insulin function and insulin receptor signaling in obese mice.55 These data strongly
support the redox and non-redox functions of TXNIP in glucose regulation and the need
to control this protein in order to treat diabetes.

1.7 Current Approaches to Modulate TXNIP
Theoretically, TXNIP’s physiological and pathophysiological effects can be
modulated by altering its synthesis, elimination, expression level, activity, binding to
ASK1 or PARP, or its localization and shuttling in the cell. Certain of these approaches
have been previously reported in the literature.
In vitro, TXNIP overexpression induces apoptosis and also interferes with glucose
metabolism.56, 57 There are several reports on the ability of insulin to suppress TXNIP.58,
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59

A study on human adipocyte cells showed that insulin was able to reduce mRNA

expression of TXNIP within four hours. In this same study, the authors examined the
effect of insulin receptor knock-out on TXNIP expression. The study found that in insulin
receptor KO mice treated with streptozotocin (STZ), insulin treatment failed to reduce
TXNIP expression, indicating that the effect of insulin on TXNIP level is mediated
through the insulin receptor.60 Other studies have shown the ability of insulin to increase
TXNIP ubiquitination and proteasomal degradation.61 cAMP activation by forskolin was
also seen to escalate TXNIP ubiquitination and proteasomal degradation.62 Metformin
activation of AMPK signaling, which has a crucial role in cellular metabolic homeostasis,
can also inhibit TXNIP expression in pancreatic β-cells.63
Verapamil and diltiazem, calcium channel blocking agents, have been shown to
suppress TXNIP expression. An in vitro study showed that TXNIP mRNA expression
and protein level were reduced with verapamil and diltiazem treatment. The same group
showed that pancreatic β-cell survival rate increased in STZ-diabetic mice with those
medications.54 Verapamil is currently undergoing a randomized controlled trial for the
reduction of TXNIP expression in β cells in type 1 diabetic patients.58 Another study has
shown that ramipril, an angiotensin-converting enzyme inhibitor, is able to suppress
TXNIP expression leading to restoration of cardiovascular homeostasis.64

1.8 Carvedilol
Carvedilol is a non-selective β-adrenoceptor blocker which also can cause
peripheral vasodilation mainly by α1-adrenergic blockade (Figure 4). Carvedilol is used
in the treatment of heart failure and hypertension. The action of carvedilol in heart failure
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is believed to be related to the β-adrenoceptor blockade. The sympathetic nervous system
is activated in heart failure leading to tachycardia and reduced ventricular filling time.
The β-adrenoceptor blockade reduces heart rate, increases filling time, and improves
cardiac output. Multiple studies suggested that, in addition to carvedilol blockade of
adrenergic receptors, it also possesses antioxidant activity.65, 66 Since oxidative stress has
been observed in heart failure, it is possible that this antioxidant activity also contributes
to carvedilol’s therapeutic effectiveness in heart failure.
This antioxidant activity of carvedilol differentiates it from other β-adrenoceptor
blockers. The mechanism of the antioxidant activity is not well understood yet, although
some studies suggest that carvedilol acts as a free radical scavenger. Some other studies
showed that carvedilol is able to suppress the enzymatic generation of ROS. There is
some evidence that the additional mechanism for carvedilol may translate to improved
therapeutic outcomes. A randomized controlled trial found that compared to metoprolol,
a selective β1 receptor blocker without antioxidant activity, carvedilol treatment in
diabetic patients with hypertension resulted in a significant reduction of the inflammation
marker microalbuminuria.67 Furthermore, the COMET Trial showed a significant
reduction in mortality with carvedilol treatment compared with metoprolol treatment in
heart failure patients.68 However, there is a need for more studies to fully understand the
antioxidant mechanism of carvedilol and its effect in cardioprotectivity.
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Figure 4. Carvedilol structure

1.9 Doxorubicin
Doxorubicin is an anthracyline compound that was first extracted from the
pigment-producing Streptomyces peucetius (Figure 5). Doxorubicin is widely used in the
treatment of a variety of cancers such as lung, thyroid, non-Hodgkin's and Hodgkin's
lymphoma, prostate and sarcoma cancers. Doxorubicin is toxic to cardiomyocytes, where
it can cause heart failure after multiple doses.69 There is strong evidence suggesting that
the mechanisms of anticancer activity are different than the mechanism of cardiotoxicity.

18
Figure 5. Doxorubicin structure

Doxorubicin can act as an intercalating agent with the cancer cells’ DNA leading
to blockade of macromolecular biosynthesis. It is also an inhibitor of topoisomerase IImediated DNA repair which will interfere with the DNA replication step. Doxorubicin
has also been shown to increase production of oxygen free radicals which can induce
destruction of other cellular structures due to lipid peroxidation, DNA breaks, and
activation of apoptotic pathways.70
Doxorubicin toxicity can be acute (approximately 11%) where it happens within
72 hours after its administration; the most common acute cardiotoxicity is arrthyhmia
development. While the occurrence of chronic doxorubicin cardiotoxicity (occurring after
a month of administration) is significantly lower (about 1.7%), it presents major clinical
treatment challenges as the chronic toxicity limits the cumulative dose of doxorubicin
that can be administered. Chronic doxorubicin toxicity has been associated with the
development of cardiomyopathy and congestive heart failure. Several studies have
suggested that doxorubicin cardiac toxicity is due to oxidative stress.71-73 The major
proposed mechanisms of doxorubicin cardiotoxicity are increased ROS and lipid
peroxidation. Doxorubicin also decreases antioxidants in cardiac muscle including GSH
and reduces activity of antioxidant enzymes such as TrxR and GPx.
It is likely that multiple mechanisms in addition to oxidative stress are
contributing to doxorubicin cardiotoxicity.70 For example, studies also showed
doxorubicin is able to inhibit nucleic acid and protein synthesis, change adrenergic
function, and reduce expression of cardiac-specific genes. Long-term administration of
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doxorubicin in vivo stimulated an early reduction in ejection fraction and decreased
sarcoplasmic reticular function.74

1.10 Research Objectives
Oxidative stress and thiol oxidative stress have been shown to be important
components in the pathogenesis of cardiovascular diseases. Therefore, finding an
effective approach to mitigating these processes is required. Since direct antioxidants
have not shown benefit in cardiovascular disease in clinical trials, alternative approaches
are needed. One such approach is to modulate the activity of endogenous antioxidant
systems such as the thioredoxin pathway.
Carvedilol is unique among other beta-blockers in that it exhibits antioxidant
activity. Studies have shown efficacy of carvedilol in diseases such as heart failure that
include a thiol oxidative stress component. The mechanism of carvedilol’s antioxidant
activity is still not fully understood. It is also unclear how this antioxidant activity
contributes to carvedilol’s efficacy in conditions where thiol oxidative stress occurs.
Previous studies in this laboratory indicated that carvedilol’s protection may involve
modulation of the thioredoxin pathway. Therefore, the objective of this study was to
measure the effect of carvedilol on the thioredoxin system, especially TXNIP, and its
related pathways in cardiomyocytes. The specific aims of this research were:
1. To examine the effect of carvedilol on the thioredoxin system in H9c2 rat
cardiomyocytes.
2. To evaluate the effect of glucose concentration and different oxidative stress
inducers on H9c2 cell viability and TXNIP expression.
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3. To explore the cardioprotective effects of carvedilol and its mechanisms in rat
cardiomyocytes against doxorubicin toxicity.
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CHAPTER 2: THE EFFECT OF CARVEDILOL ON THE THIOREDOXIN
PATHWAY IN H9C2 CELLS
2.1 Introduction
Thioredoxin (Trx), thioredoxin reductase (TrxR), and thioredoxin-interacting
protein (TXNIP) are the major proteins in the thioredoxin system, a thiol oxidoreductase
system involved in maintenance of cellular redox status. The Trx active site includes a
Cys-Gly-Pro-Cys motif which reduces disulfide bonds in other proteins, creating a
disulfide bond in the Trx active site in the process which is then reduced by TrxR. The
two isoforms of these proteins are localized in different places within the cell; Trx1 and
TrxR1 are mainly found in the cytoplasm, while Trx2 and TrxR2 are found in the
mitochondria. TXNIP, also known as thioredoxin binding protein-2 (TBP-2) and vitamin
D3 upregulated protein (VDUP1), was originally identified as a negative regulator of
Trx1; TXNIP forms a mixed disulfide with reduced Trx, therefore inhibiting its
interaction with other proteins.3 In addition to regulation of redox status, the thioredoxin
system regulates other pathways including apoptosis, cell cycle regulation, and glucose
metabolism.21, 75, 76
Redox state imbalances have been implicated in a number of disease states,
including cardiovascular disorders such heart failure, diabetic cardiomyopathy, and
ischemia-reperfusion injury.77-79 Since the thioredoxin system is an important regulator of
cellular redox state and apoptosis, involvement of this pathway in cardiovascular
disorders is an area of research interest. Previous research has shown upregulation of
Trx1 or Trx2 is beneficial in protecting the heart from oxidative damage and inhibiting
cardiomyocyte apoptosis.80, 81 On the other hand, TXNIP has been associated with the
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development of cardiovascular disorders. Overexpression of TXNIP has been reported to
induce oxidative stress through inhibition of Trx activity and apoptotic cell death through
activation of ASK1, while knockdown of TXNIP in cardiomyocytes inhibits apoptosis
and improves cell survival.82-85 Because of this role of the thioredoxin-related proteins in
cardiovascular disorders, the pathway is a potential target for drug development.
Carvedilol, a non-selective a/β-blocker, is used clinically in the management of
cardiovascular disorders such as heart failure. In addition to the adrenergic receptor
blockade, carvedilol has also demonstrated antioxidant and antiapoptotic activities.86
Previous literature reports have also shown that carvedilol can impact endogenous
antioxidant pathways. Carvedilol induced a reduction in the ratio of reduced to oxidized
glutathione and increased the activity of the enzyme glutathione peroxidase.87-91 Two
previous studies have examined the effect of carvedilol on Trx1 expression. The first
study showed upregulation of thioredoxin expression in vascular smooth muscle cells
treated with the active enantiomer of carvedilol.92 A recent article reported an increase in
Trx1 expression following carvedilol treatment in spontaneously hypertensive rats.93     
The objective of this study was to conduct a comprehensive evaluation of carvedilol’s
impact on proteins in the thioredoxin system.
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2.2 Materials and Methods
2.2.1 Reagents and Antibodies
Carvedilol (Sigma, C3993) was dissolved in DMSO; the final concentration of
DMSO in cell culture studies was 0.2%. Propranolol (Sigma, P0884), atenolol (Sigma,
A7655) and metoprolol (Sigma, M5391) were dissolved in water. MG132 (Santa Cruz,
sc351846) and verapamil (Sigma, V-4629) were dissolved in ethanol. For RNA
extraction, TRIzol reagent was purchased from Invitrogen (15596-026) and AccessQuick
RT-PCR system from Promega (A1701).
Trx1and PARP antibodies were purchased from Cell Signaling Technology
(2298S and 9542); TrxR1 and TXNIP antibodies were obtained from Novus Biologicals,
Inc (NBP2-27095 and NBP2-20619); antibodies to Trx2, TrxR2, Lamin A/C, actin,
pERK, and secondary antibody goat anti-rabbit were purchased from Santa Cruz
Biotechnology (sc-133201, sc-376868, sc-376248, sc-2004 and sc-7210); and the goat
anti-mouse secondary antibody was obtained from Bio-Rad (170-6516).

2.2.3 Cell Culture
H9c2 rat embryonic cardiac myoblasts were purchased from the American Type
Culture Collection (ATCC, Manassas, VA, USA) and maintained in Dulbecco’s modified
Eagle’s medium (DMEM, ATCC). The CV-1 monkey kidney cell line was obtained from
ATCC and maintained in Roswell Park Memorial Institute medium (RPMI 1640,
HyClone, SH3002701). All medium contained 10% (v/v) fetal bovine serum and 1%
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(v/v) penicillin/streptomycin, and cells were maintained at 37°C with 5% CO2. Only
cells with passage number below 20 were utilized.
2.2.4 Evaluation of Proteins in the Thioredoxin Pathway by Western Blot
Western blot was used to determine the protein level of TXNIP, Trx1, and TrxR1.
Two million H9c2 cells were seeded to 75 cm2 flasks and allowed to attach overnight.
The cells were then treated with carvedilol 10 µM for 24 or 48 hours. Control cells were
incubated with medium containing vehicle. Verapamil (50 and 100 µM) was used as a
positive control in TXNIP analysis. TXNIP level was evaluated with other beta-blockers
(propranolol, atenolol, and metoprolol; 10 µM) for comparison. TXNIP Western blot was
also conducted in an additional cell line; in this study, two million CV-1 cells were
treated with carvedilol 10 µM for 24 or 48 hours. Cells were collected by trypsinization
and centrifuged at 1000 x g for 5 minutes. The cells were lysed in lysis buffer containing
20 mM HEPES (pH 7.4), 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
and 1× broad-spectrum protease inhibitors (Thermo Fisher Scientific, 88665). Total
protein concentrations were determined using the Bradford protein assay, and samples
containing between 25-50 µg of protein were separated by 8% or 12% SDS-PAGE
followed by transfer onto PVDF membranes. The membranes were blocked using 0.5%
bovine serum albumin (BSA; Sigma, A3294) for 3 hours followed by incubation with
primary antibody (1:10,000) for 12 hours. HRP-conjugated secondary antibody was then
added for 1 hour at room temperature. Visualization was conducted using a kit from GE
Biosciences and quantified using a Bio-Rad imaging system. Actin was used as the
housekeeping protein. In addition, a Western blot for phosphorylated ERK was
conducted following the same procedure.
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2.2.5 Rt-PCR
Rt-PCR was performed according to the manufacturer’s instructions (Promega).
mRNA extracted from H9c2 cells was reverse transcribed (45 minutes at 45 °C) to cDNA
using AMV reverse transcriptase followed by amplification of the cDNA product using
PCR. The cDNA template was denatured at 94°C for 2 minutes followed by the 20/30/40
cycles, with each cycle having denaturation (94°C for 30 second, annealing (60°C for 60
seconds) and extension (60°C for 120 seconds), except for the last extension which was
performed at 68°C for 5 minutes and held at 4°C. 1.2 % agarose gel containing ethidium
bromide was used to run the PCR products. Primers used for PCR genotyping were:
TXNIP-FORWARD, 5’-TCAACGCTTTCTGCCTCTCT-3’
TXNIP-REVERSE, 5’-ACACCTTGGAAAGACCATGC-3’
GAPDH-FORWARD, 5’-CAACTCCCTCAAGATTGTCAGCAA-3’
GAPDH-REVERSE, 5’-GGCATGGACTGTGGTCATGA-3’
2.2.6 Proteasomal Inhibition
In order to investigate the impact on proteasomal degradation of TXNIP, two
million H9c2 cells were placed in a 75 cm2 flask and allowed to attach overnight. Cells
were exposed to the proteasomal inhibitor MG-132 for 2 hours followed by treatment
with carvedilol 10 µM or vehicle for 24 hours. The cells were collected by trypsinization
and centrifuged at 1000 x g for 5 minutes. Cells were lysed in lysis buffer and Western
blot was conducted as described above.
2.2.7 Isolation of Mitochondrial Fractions from H9c2 Cells
Ten million H9c2 cells were seeded in petri dishes (100 mm) and allowed to
attach overnight. The cells were then treated with carvedilol 10 µM for 24 hours. Control
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cells were incubated with medium containing vehicle. Mitochondrial fractions were
isolated using a mitochondria isolation kit for cultured cells (Thermo Fisher Scientific,
89874), as per manufacturer's instructions. Western blot was conducted for Trx2, TrxR2
and TXNIP as described above. Cytochrome c was used as the housekeeping protein.
2.2.8 Cell Fractionation and Nuclear Isolation
The cytoplasmic and nuclear fractions were isolated as previously described. 94
H9c2 cells were seeded in 100-mm petri dishes overnight and then treated with carvedilol
10 µM for 24 hours. Then cells were washed twice with cold phosphate buffered saline
(PBS) and collected by scraping with 5 mL of hypotonic buffer [10 mM KCl, 1.5 mM
MgCl2, 1 mM sodium orthovanadate, 1 M Tris and 1x protease inhibitors (Thermo
science #88665)]. The cells were centrifuged at 1000 x g for 10 minutes at 4°C. The
pellet was resuspended in 600 µL of cold hypotonic buffer. A loose fitting Dounce
homogenizer over ice was used to gently separate the cytoplasmic and nuclear fractions
followed by centrifugation (1000 x g for 7 minutes at 4°C). The nuclear fraction
contained in the pellet was extracted with cold high salt buffer (10 mM Tris-Cl, pH 7.4,
400 mM NaCl, 25% glycerol and 1x protease inhibitors) for 30 minutes at 4°C and then
centrifuged at 20817 x g at 4°C for 10 min. The supernatant was used for Western blot
analysis as described above. Actin was used as the housekeeping protein.
2.2.9 Immunoprecipitation
H9c2 cells were treated with carvedilol 10 µM for 24 hours. Following treatment,
the cells were washed with PBS and scraped using lysis buffer. Protein concentrations
were determined using the Bradford protein assay. 300 µg total protein was
immunoprecipitated with agarose-conjugated anti-PARP or anti-TXNIP antibody in 1 mL
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of lysis buffer overnight at 4°C. The immunocomplexes were captured by adding 55 µL
of protein G agarose and incubated for 3 hours at 4°C. Then the immunocomplexes were
spun down at 300 RPM for 10 minutes and the pellet was washed three times with lysis
buffer. The pellet was collected and suspended in SDS-sample buffer, boiled for 10
minutes, and then Western blot was conducted using anti-TXNIP or anti-Trx1 antibody.
2.2.10 Thioredoxin Activity Assay
H9c2 cells were harvested and lysed with lysis buffer (20mM HEPES at pH 7.4,
1% Triton X-100, 150mM NaCl, 1mM EDTA, 1mM EGTA, and 1× protease arrest). Trx
activity was measured using a fluorescence assay kit (Cayman IMCO Corp., #FkTRX02-V2), following the manufacturer’s protocol. Briefly, the assay is based on the
reduction of a disulfide bond in insulin by Trx. The insulin in the assay is labeled with
eosin allowing for detection of Trx activity by fluorescence as the reduced insulin
exhibits higher fluorescence compared to oxidized insulin. Around 10 µg of protein
extract was used in the assay. Fluorescence was detected using an excitation wavelength
of 520 nm and an emission wavelength of 545 nm. The increase in fluorescence was
observed for 60 minutes. A standard curve was constructed using human recombinant
Trx1.
2.2.11 Statistical Analysis
Data are expressed as means ± standard deviation (SD) from three independent
experiments. Statistical analysis was done using ANOVA followed by Tukey’s post hoc
test. A p value of <0.05 was considered to be statistically significant.

28
2.3 Results
2.3.1 Carvedilol’s Impact on Major Thioredoxin Proteins: Trx1, TrxR1, Trx2,
TrxR2 and TXNIP
The protein level of TXNIP, Trx1, and TrxR1 was determined in the cytosol
following 10 µM carvedilol treatment for 24 and 48 hours. The mitochondrial isoforms
Trx2 and TrxR2 were evaluated in the mitochondria after a 24 hour treatment. The
cytosolic level of TXNIP decreased significantly with carvedilol treatment for 24 hours
compared to control; this decrease was sustained at 48 hours. The positive control
verapamil also reduced cytosolic TXNIP expression by 40% (Figure 6). Protein
expression for Trx1, TrxR1, Trx2, and TrxR2 was not statistically significantly different
from control at either time point (Figures 7 & 8).
In order to investigate if the reduction in TXNIP was cell line specific, TXNIP
Western blots were conducted in CV-1 cells. A similar decrease in TXNIP in the cytosol
was observed in the CV-1 cell line (Figure 9).
The time dependence of the effect of carvedilol on TXNIP expression was
evaluated using Western blot. H9c2 cells were treated with carvedilol for 2, 4, 12, 24, 48,
and 72 hours. No changes in TXNIP were observed through 12 hours; the decrease in
cytosolic TXNIP was observed starting at 24 hours and was sustained through 48 and 72
hours (Figure 10).
2.3.2 Comparison with Other Beta-Blockers
To determine if the reduction in TXNIP is a class effect, three other beta-blockers
were selected to represent the pharmacologic class. Propranolol is a nonselective betablocker like carvedilol while atenolol and metoprolol represent the beta-1 selective
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agents. No decrease in TXNIP was observed with any of the other beta-blockers
indicating that this may be a unique feature of carvedilol (Figure. 11).
2.3.3 Investigation of the mechanism of TXNIP Reduction
Since the protein level of TXNIP was reduced, rt-PCR was conducted to
determine if gene expression was also changed. No change in TXNIP mRNA was found
at either time point (24 and 48 hours) indicating that a change in gene expression was not
responsible for the change in TXNIP protein level (Figure 12).
Proteasomal degradation of TXNIP was investigated using MG132, a non-specific
proteasome inhibitor. If enhanced proteasomal degradation was responsible for the
decrease in TXNIP observed with carvedilol exposure, proteasomal inhibition should
reverse the effects. However, the reduction in TXNIP was still observed in the presence
of MG132 (Figure 13).
2.3.4 Impact of Carvedilol on TXNIP Localization in Nucleus and Mitochondria
TXNIP is known to traffic between the nucleus, cytosol, and mitochondria.
Therefore, TXNIP levels in subcellular fractions were determined. A statistically
significant increase in TXNIP was found in the nuclear fraction (Figure 14). However, no
change in TXNIP in the mitochondria was observed (Figure 15). This indicates that the
reduction of TXNIP in the cytosol occurred due to enhanced sequestration of TXNIP in
the nucleus. Lamin A/C protein was used for subcellular fractions verifying that the
nuclear fractions were successfully separated from the cytosol. Similarly, cytochrome c
was used to verify the mitochondrial isolation.
Because ERK signaling has been reported to be connected to importin-alpha
nuclear transport, Western blot was conducted in H9c2 cells to measure the effect of 10
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µM carvedilol treatment for 24 hours on pERK expression. We observed a significant
increase in pERK expression from carvedilol treatment (Figure 16).

2.3.5 Effect of carvedilol on TXNIP-PARP and TXNIP-Trx1 Protein Complexation
TXNIP is known to be complexed with PARP in the nucleus.95 To verify the
increase of TXNIP in the nuclear fraction, immunoprecipitation was performed for the
PARP-TXNIP complex. Following immunoprecipitation with anti-PARP antibody,
Western blot of untreated cells showed the presence of TXNIP indicating that the
complex between TXNIP and PARP was present under normal conditions. The carvedilol
treated samples showed an increase in the PARP-TXNIP complex providing further
confirmation of increased TXNIP localization in the nucleus (Figure 17A).
Immunoprecipitation was also performed to determine the effect of carvedilol on the
TXNIP-Trx1 complex in the cytosol. Carvedilol significantly decreased the TXNIP-Trx1
complex after 24 hours of treatment (Figure 17B).
2.3.6 Effect of Carvedilol on Trx1 activity
To illustrate the effect of carvedilol treatment on Trx1 activity, cells were treated
with 10 µM of carvedilol for 24 hours; then Trx1 activity in lysed cells was compared
with a standard curve. The activity of Trx1 did not change between the control and
treatment (Figure 18).
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Figure 6. Effect of 10 µM carvedilol treatment on TXNIP in H9c2 cells after 24 and 48
hours of treatment. 100 µM Verapamil was used as a positive control.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. Two-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. ** p < 0.01 compared with control group.
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Figure 7. Effect of 10 µM carvedilol treatment on Trx1 and TrxR1 in H9c2 cells after 24
and 48 hours of treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. Two-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. ** p < 0.01 compared with control group.
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Figure 8. Effect of 10 µM carvedilol treatment on Trx2 and TrxR2 protein expression in
H9c2 cells after 24 and 48 hours of treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. Two-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. ** p < 0.01 compared with control group.
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Figure 9. Effect of 10 µM carvedilol treatment on TXNIP protein expression in CV-1
cells after 24 and 48 hours of treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. Two-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. ** p < 0.01 compared with control group.
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Figure 10. Time dependent effect of 10 µM carvedilol on TXNIP protein in H9c2 cells
for 2, 4, 12, 24, 48 and 72 hours.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. Two-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point.
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Figure 11. Effect of propranolol, atenolol and metoprolol on TXNIP protein expression in
H9c2 cells for 24 hours.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data.
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Figure 12. Effect of 10 µM carvedilol on TXNIP mRNA expression as measured by
PCR. H9c2 cells were treated for 24 and 48 hours, before isolating mRNA.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. Two-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point.
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Figure 13. Effect of protease inhibitor MG132 on carvedilol mediated degradation of
TXNIP. H9c2 cells were treated for 24 hours.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. Two-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point.
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Figure 14. Effect of 10 µM carvedilol on nuclear and cytoplasmic expression of TXNIP
protein in H9c2 cells after 24 hours of treatment.
Lamin A/C was used to examine the purity of nuclear separation. The data are presented
as relative intensity (protein/actin) and expressed as the means ± SD of three independent
experiments. Two-way ANOVA and Tukey’s post hoc test were performed to analyze
data at each time point. * p < 0.05 and ** p < 0.01 compared with control group.
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Figure 15. Effect of 10 µM carvedilol on mitochondrial expression of TXNIP protein in
H9c2 cells after 24 and 48 hours of treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. Two-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point.
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Figure 16. Effect of 10 µM carvedilol on expression of pERK in H9c2 cells after 24
hours of treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. ** p < 0.01 compared with control group.
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Figure 17. (A) Anti-TXNIP antibody immunoblots of untreated and 10 µM carvedilol
treated samples immunoprecipitated with anti-PARP antibody. (B) anti-Trx1antibody
immunoblots of untreated and 10 µM carvedilol treated samples immunoprecipitated
with anti-TXNIP antibody.
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Figure 18. The effect of carvedilol treatment on Trx1 activity.
The data are presented as fluorescence intensity as the means ± SD of three independent
experiments. One-way ANOVA and Tukey’s post hoc test were performed to analyze
data at each time point.
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2.4 Discussion
The present study was designed to explore the effect of carvedilol on the
thioredoxin system in H9c2 cells. It was found that carvedilol treatment induced a
statistically significant reduction in TXNIP in the cytosol. Further mechanistic studies
showed that this reduction was not caused by decreased gene expression or increased
protein degradation; instead, an increase in TXNIP in the nucleus was observed.
Furthermore, carvedilol was also found to increase TXNIP-PARP complexation in the
nuclear fraction and decrease TXNIP-Trx1 complexation in the cytosol.
Verapamil, a calcium channel blocker, has been reported to reduce TXNIP
expression in vitro and in vivo.53, 54 In fact, verapamil is currently in clinical trials for
TXNIP reduction in type 1 diabetes.96 Therefore, verapamil was utilized as a positive
control in this study. A similar reduction of TXNIP in the cytosol was observed between
verapamil and carvedilol; however, the mechanism of reduction appears to be different
between the two drugs. In response to verapamil treatment in mice, quantitative real-time
rt-PCR showed a significant decrease in the gene expression of TXNIP.53 No change in
TXNIP mRNA was observed with carvedilol in this study indicating that a reduction in
gene expression is not responsible for the decrease in TXNIP. Another study has shown
that insulin was able to reduce the TXNIP level by degradation via the proteasomal
pathway in pancreatic INS-1 cells.27 The decrease in TXNIP by carvedilol was not
reversed by proteasomal inhibition by MG132 indicating that this is also not the
mechanism for carvedilol’s reduction in TXNIP.
Endogenous TXNIP is known to shuttle between subcellular compartments. In the
cytosol, TXNIP is found complexed with Trx under normal conditions.97 Importin α was
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found to move TXNIP between the cytosol and nucleus.76, 98 PARP is a nuclear protein
activated by DNA damage associated with oxidative stress.99Studies have shown that
under basal conditions PARP complexes with TXNIP, preventing it from migration to the
mitochondria. In this study, carvedilol treatment showed a significant increase in TXNIP
in the nucleus with an accompanying increase in TXNIP-PARP complexation. The
reduction of cytosolic TXNIP with carvedilol treatment was accompanied by a decrease
in TXNIP-Trx1 complexation in the cytosol. Because the total amount of Trx1 in the
cytosol remained unchanged with carvedilol treatment, the reduction in the complex
indicates that there would either be an increase in free Trx or an increase in Trx1
complexation with other proteins such as the pro-apoptotic ASK1. This indicates that
carvedilol may be reducing oxidative stress and/or protecting cells against apoptosis via
modulation of the thioredoxin pathway. The mechanism by which carvedilol increases
TXNIP accumulation in the nucleus is not known and will require further study.
TXNIP has also been shown to translocate to the mitochondria in response to
oxidative stress.98, 100, 101 Under oxidative stress, TXNIP shuttles to the mitochondria and
binds to Trx2, which will lead to ASK1 release mediating cell apoptosis.64 Since these
studies were not conducted in cells undergoing oxidative stress, no change in Trx2,
TrxR2, and TXNIP in the mitochondria was expected. The results confirmed that there
was no change in Trx2 or TrxR2 with carvedilol treatment, and TXNIP was not detected
in the mitochondria.
Our hypothesis was that Trx activity would increase with carvedilol treatment due
to the decrease in the cytosolic TXNIP. Unexpectedly, no change in Trx activity was
observed. A literature search revealed another study were Trx activity did not change
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with a decrease in TXNIP. This study found that TXNIP knockout produced
cardioprotection independent of Trx activity.106 This indicates that a change in Trx
activity would not be required for carvedilol to have a positive impact on cardiac function
through TXNIIP modulation. On other hand, the literature indicates that ERK signaling
may be involved in nuclear translocation.102 Another study showed that TXNIP knockout
was associated with a significant increase in phosphorylation of ERK. That is consistent
with our findings as pERK significantly increased with the reduction of TXNIP in the
cytosol and its increase in the nucleus.
In conclusion, carvedilol treatment in H9c2 cells produced an increase in TXNIP
in the nucleus paired with increased PARP-TXNIP complexation. This potentially could
impact oxidative stress and apoptosis in cardiomyocytes treated with carvedilol. Further
studies will reveal the impact of increased nuclear TXNIIP on oxidative stress and
apoptosis.
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CHAPTER 3. THE EFFECT OF GLUCOSE CONCENTRATION AND OXIDATIVE
STRESS ON TXNIP LEVEL IN H9C2 CELLS.
3.1 Introduction
Thioredoxin-interacting protein (TXNIP), also known as vitamin D-upregulated
protein (VDUP1) or thioredoxin-binding-protein-2 (TBP2), acts as a biological negative
regulator for the thioredoxin (Trx) protein. TXNIP has been identified as an important
protein in both physiologic and pathophysiologic conditions. The main physiological
effect TXNIP has is its ability to regulate the cellular redox state by binding and
preventing Trx in a redox dependent manner. TXNIP is also a member of the α-arrestin
superfamily of proteins and can utilize redox independent mechanisms such as acting like
a cell growth regulator, a tumor suppressor gene, regulator of cell apoptosis, and
modulator of the inflammatory response.10
Numerous studies have shown that TXNIP plays a significant role in the
pathogenesis of diabetes. TXNIP expression was found to be induced in pancreatic βcells under high glucose conditions. TXNIP reduction in a diabetes mouse model
improved insulin function and decreased glucose level.54 Knocking out TXNIP in obese
mice increased insulin function and signaling of the insulin receptor.55 Verapamil, a
calcium channel blocker, is currently undergoing randomized controlled trials for its
ability to decrease TXNIP expression in β cells in type 1 diabetic patients.58 These data
strongly support the important role of TXNIP redox and non-redox functions in glucose
regulation and the need to better regulate this protein in order to treat diabetes and related
conditions such as diabetic cardiomyopathy.
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Literature reports have shown the significant role of TXNIP in cardiovascular
disease development. In neonatal rat ventricular myocytes cells (NRVM), TXNIP
expression was significantly increased in response to ROS induction in concentrationdependent manner.49 Diabetic cardiomyopathy is a cardiac dysfunction associated with
diabetic patients where hyperglycemia in the heart leads to ventricular dysfunction and
heart failure. A study diabetic mouse hearts showed that deletion of the TXNIP gene will
enhance cardiac inotropy leading to enhanced cardiac function in those mice.60

Under oxidative stress, TXNIP is able to block the function and activity of Trx by
competitively binding to Trx and preventing it from binding to other proteins such as
ASK1. TXNIP can inhibit Trx via formation of a mixed disulfide bond with the active
site motif of reduced Trx. High expression of TXNIP under oxidative stress can reduce
Trx activity leading to an increase in protein oxidation in the cell.

In the previous chapter, we have seen that carvedilol, an antioxidant beta blocker,
has the ability to decrease TXNIP expression in H9c2 cells under normal conditions.
Carvedilol was able to move TXNIP to the nucleus and increased its complexation with
the PARP protein. However, much is still unknown about the effect of glucose
concentration and reactive oxygen species inducers in TXNIP expression in normal
cardiac cells. Therefore, our objectives in this study were:

1. To evaluate the cell viability of H9c2 cells under different concentrations of
glucose
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2. To determine the effect of glucose concentration on TXNIP expression in H9c2
cells
3. To measure TXNIP expression under different oxidative stress induction
conditions in H9c2 cells
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3.2 Materials and Methods
3.2.1 Reagents and Antibodies
Doxorubicin (SIGMA, D1515) was dissolved in DMSO to make a 0.5 mM stock
solution and was filtered using a Medical Millex-GP filter (0.22 µm, sterilized;
Millipore). The final concentration of DMSO in cell culture studies was less than 0.2%.
Stock solutions were saved at -80°C and were diluted in growth medium to the desired
concentrations for cell culture treatment. TXNIP antibody was obtained from Novus
Biologicals, Inc (NBP2-20619). Actin antibody and secondary antibody goat anti-rabbit
were purchased from Santa Cruz Biotechnology (sc-2004 and sc-7210).
3.2.2 Cell Culture
In this study, rat embryonic cardiac myoblasts, H9c2 cells, were purchased from
the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in
Dulbecco’s modified Eagle’s medium (DMEM, ATCC). Growth medium contained 10%
(v/v) fetal bovine serum and 1% (v/v) penicillin/streptomycin, and cells were maintained
at 37°C with 5% CO2. All experiments were performed in a passage number below 20.
3.2.3 Cell Viability
H9c2 cells were seeded and treated in a 96-well plate, and cell viability was
measured by colorimetric assay containing MTT (3-(4, 5)-dimethylthiazol-2, 5diphenyltetrazolium bromide). H9c2 cells with density of 1,000 cells/well were seeded
and allowed to attach overnight. Growth medium was then removed, and medium with no
glucose, 25mM glucose, or 50 mM glucose was added to the cells for 3 days. Then MTT
assay was conducted by replacing the medium with medium containing 0.5 mg/ml MTT
solution (50 µl/well) and incubated in the dark at 37°C for 4 hours. DMSO was used to
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dissolve the formed purple formazan product (150 µl/well for one hour). A SpectraMax
M2 microplate reader (Molecular Devices, Sunnyvale, CA, USA) was used to measure
the absorbance of each well by using a test wavelength of 570 nm and a reference
wavelength of 650 nm.
3.2.4 Glucose Effect on TXNIP Protein Expression in H9c2 Cells
Two million H9c2 cells were seeded in 75 cm2 flasks and allowed to attach
overnight. Medium with no glucose, 25 mM glucose, or 50 mM glucose was added for 24
hours. Then cells were detached using trypsin and centrifuged at 1000 x g for 5 minutes.
The cells were separately lysed in lysis buffer containing 20 mM HEPES (pH 7.4), 1%
Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 1× broad-spectrum
protease inhibitors (Thermo Fisher Scientific, 88665). Bradford protein assay was used to
determine the total protein concentration, and samples containing 50 µg of protein were
separated by 8% SDS-PAGE followed by transfer onto PVDF membranes. 0.5% bovine
serum albumin (BSA; Sigma, A3294) was used to block the membranes for 3 hours
followed by incubation with primary antibody (1:10,000) overnight. HRP-conjugated
secondary antibody was then added for 1 hour at room temperature. Visualization of the
bands was performed using a kit from GE Biosciences and quantified using a Bio-Rad
imaging system. For this experiment, actin was used as a housekeeping protein.
3.2.5 Doxorubicin Treatment
Two million H9c2 cells were seeded in 75 cm2 flasks and allowed to attach
overnight. The cells were then treated with doxorubicin 0.5 µM. Control flasks were
incubated with medium containing vehicle during the treatment period. Sample collection
and western blot was performed as described above.
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3.2.6 Hypoxia and Reoxygenation
Hypoxia and reoxygenation were conducted using a method reported by Liao et
al, with minor modification.104 Two million H9c2 cells were seeded in 75 cm2 flasks and
allowed to attach overnight in 25 mM glucose DMEM. Cells then were washed with PBS
buffer twice, and new medium was added. The flask then was placed for 6 hours in a
hypoxia chamber, saturated with 5% CO2/95% N2. After that, cells were incubated for
reoxygenation in an incubator containing 5% CO2 at 37°C for another 24 hours.
3.2.7 Radiation Procedure
Two million H9c2 cells were seeded in 75 cm2 flasks and allowed to attach
overnight in DMEM. A single dose of 40 Gy of X-rays for 5 minutes was directed to the
cells using a 160-kVp X-ray high energy linear accelerator using Faxitron cabinet
irradiator (Faxitron Bioptics, Lincolnshire, IL).
3.2.8 Statistical Analysis
Data are expressed as means ± standard deviation (SD) from three independent
experiments. Statistical analysis was done using ANOVA followed by Tukey’s post hoc
test. A p value of <0.05 was considered to be statistically significant.
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3.3 Results
3.3.1 Glucose Concentration Effect on Cell Viability
The regular growth medium (DMEM) for H9c2 cell growth contains 25 mM
glucose. Since different glucose concentrations would be utilized for the study of TXNIP
expression, a cell viability assay was conducted to determine the effect of glucose
concentration on H9c2 cell viability. An MTT assay was conducted to determine cell
viability in cells incubated with 50 mM glucose, 25 mM glucose, or no glucose for 72
hours. No significant change in cell viability with the different glucose concentrations
was observed (Figure 19).
3.3.2 Impact of Glucose Concentration on TXNIP Expression
H9c2 cells were treated with different concentrations of glucose and TXNIP
expression was measured. TXNIP level was increased significantly with increasing
glucose concentration. When incubated with glucose free DMEM compared to 25 mM
glucose DMEM, H9c2 cell expression of cytosolic TXNIP was significantly reduced to
less than 50% of the normal level (Figure 20). When the glucose concentration was
doubled to 50 mM, the cells exhibited a 1.5-fold increase in TXNIP expression (Figure
21).
3.3.3 Impact of Doxorubicin Treatment on TXNIP Expression
H9c2 cells were treated with 0.5 µM doxorubicin, and TXNIP expression was
measured by western blot. The expression of TXNIP was decreased around 50% with
doxorubicin exposure (Figure 24).
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3.3.4 Effect of Hypoxia Reoxygenation on TXNIP Expression
H9c2 cells were reoxygenated for 24 hours after 6 hours of hypoxia, and TXNIP
expression was measured by western blot. TXNIP expression decreased around 60% with
this hypoxia-reoxygenation procedure (Figure 23).

3.3.5 Effect of Radiation on TXNIP Expression
H9c2 cells were exposed to a single dose of 40 Gy of X-rays for 5 minutes, and
TXNIP expression was measured by western blot. This dose slightly decreased TXNIP
expression, but this did not reach statistical significance (Figure 22).
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Figure 19. Cell viability assay in H9c2 cells with no glucose, 25mM glucose and 50 mM
glucose and growth medium for 3 days.
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Figure 20. Effect of no glucose medium on cytoplasmic TXNIP protein expression in
H9c2 cells after 24 hours treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. ** p < 0.01 compared with control group.
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Figure 21. Effect of 50mM glucose medium on cytoplasmic TXNIP protein expression in
H9c2 cells after 24 hours treatment.
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Figure 22. Effect of a single dose of 40 Gy of X-rays for 5 minutes on cytoplasmic
TXNIP protein expression in H9c2 cells after 24 hours treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point.
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Figure 23. Effect of hypoxia-reoxygenation procedure on cytoplasmic TXNIP protein
expression in H9c2 cells after 6 hours hypoxia and 24 hours reoxygenation.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point.

60

Figure 24. Effect of 0.5 µM doxorubicin treatment on cytoplasmic TXNIP protein
expression in H9c2 cells after 24 hours treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. ***p < 0.001 compared with control group.

61
3.4 Discussion
This present study was designed to examine the effect of glucose concentration on
cytosolic TXNIP expression in H9c2 cells. It also showed the effect of different oxidative
stress inducers on cytosolic TXNIP. It was found that TXNIP expression significantly
increased with higher concentrations of glucose. Furthermore, 0.5 µM doxorubicin
significantly decreased TXNIP expression. Similar to doxorubicin, reoxygenation of cells
after hypoxia conditions led to TXNIP reduction. Exposing cells to 40 Gy of X-rays for 5
minutes did not significantly affect TXNIP expression.
TXNIP has an important role in the pathogenesis of diabetes.52, 54, 55 It has been
shown that TXNIP has multiple metabolic effects which cause or augment diabetes, such
as increasing production of glucose in the liver and causing β-cell dysfunction.79 Clinical
trials are ongoing for the therapeutic application of reducing TXNIP expression in
diabetes. H9c2 cells regularly grow in 25 mM glucose. Consistent with observations
made in other cell types, cytosolic TXNIP was significantly increased with increased
glucose concentration in the growth medium and significantly reduced in glucose free
medium.
As previously described, TXNIP has been shown to have a variety of negative
effects on glucose regulation. Since an increase in cytosolic TXNIP was observed with
hyperglycemia in the cardiac cells, modifying TXNIP expression under hyperglycemic
conditions might be a good therapeutic target for diabetic cardiomyopathy. Diabetic
cardiomyopathy is a form of heart failure that occurs in diabetic patients but is not related
to a specific cardiovascular abnormality such as hypertension. The exact cause of diabetic
cardiomyopathy is not known, but several abnormalities have been associated with the
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development of this condition. One of those abnormalities is increased production of free
radicals and reactive oxygen species. Cai, et al found that diabetic mice induced by STZ
exhibited higher levels of lipid peroxidation. Thiol oxidative stress was also observed in
this study with an imbalance in mitochondrial reduced versus oxidized glutathione.105 The
thioredoxin pathway has also been implicated in the development of diabetic
cardiomyopathy. Decreased expression of mitochondrial Trx2 was found in H9c2 cells
grown in high glucose growth medium. The same study found reduced expression of
Trx2 in STZ diabetic rats.10 A recent study examined the effect of glucose concentration
on expression of TXNIP in H9c2 cells. The authors found that increasing concentrations
of glucose up to 25 mM significantly increased TXNIP.106 Our results further extend this
up to 50 mM glucose, and additional increases in cytosolic TXNIP were observed. The
same study found that TXNIP knockout mice exhibited improved cardiac function
following induction of diabetes by STZ compared to wild type mice.10 This important
finding demonstrates the potential of TXNIP modulation in therapy of diabetic
cardiomyopathy.
Doxorubicin is an anthracyline agent used to treat several types of cancer. It has a
high toxicity especially in cardiac cells because of its ability to increase ROS production
which can lead to heart failure.69 Impact on the thioredoxin pathway by doxorubicin has
been previously observed as doxorubicin is known to inhibit TrxR.107 However, no
reports on doxorubicin’s impact on TXNIP are available. In this study, cytosolic TXNIP
expression was decreased significantly with doxorubicin treatment. This is likely because
of increased ROS production which is known to move TXNIP to the mitochondria.
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Ischemia-reperfusion injury is another important oxidative stress-mediated insult
to the heart. Ischemia-reperfusion injury occurs after heart cells that were previously
deprived of oxygen (for example, in a myocardial infarction) are reperfused. Reactive
oxygen species are produced quickly after the reintroduction of oxygen to the cells. The
source of these reactive oxygen species is not clear but may include leakage of radicals
from the mitochondria or activation of immune system cells.103 In this study, ischemiareperfusion injury was modeled using a hypoxia chamber followed by reintroduction to
the regular oxygen environment of a normal incubator.108 Similar to doxorubicin, we saw
a significant decrease in cytosolic TXNIP expression with the hypoxia-reoxygenation
process. These results show that TXNIP expression is affected by cellular redox status
and the presence of ROS in the system.
Radiation is a well known source of oxidative stress in cells by causing generation
of ROS leading to apoptosis.109 According to previous work in this laboratory, 40 Gy of
radiation from X-rays will cause stress to H9c2 cells but with little mortality (data not
published). In this study, exposing cells to 40 Gy of X-ray radiation showed a trend
toward decreasing TXNIP expression, but it did not reach a statistically significant level.
With increasing radiation doses, it is possible that the reduction may be more significant
with increasing levels of oxidative stress.
In conclusion, both glucose level and oxidative stress impact the cytosolic
concentration of TXNIP in H9c2 cardiomyocytes. The impact of hyperglycemia on
TXNIP is consistent with other literature reports. The reduction in cytosolic TXNIP is
consistent with the movement of TXNIP to the mitochondria. Because of the clear
reduction of TXNIP from doxorubicin treatment and the clinical relevance of doxorubicin
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cardiotoxicity, doxorubicin was selected to move forward for a more detailed study of the
effect on TXNIP and related proteins.
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CHAPTER 4. THIOREDOXIN PATHWAY MODULATION BY CARVEDILOL AND
DOXORUBICIN TOXICITY IN H9C2 CELLS
4.1 Introduction
Doxorubicin is an antitumor antibiotic belonging to the anthracycline family. It is
an important antineoplastic agent with topoisomerase-inhibiting and DNA intercalating
activity.72 It is often used alone or combined with other agents to treat a variety of
cancers such as lymphoma, breast cancer, bladder cancer, ovarian cancer and prostate
cancer. Cardiac toxicity is the major dose dependent side effect. Both acute and chronic
cardiotoxicity can occur. The chronic toxicity manifests primarily as a dilated
cardiomyopathy. Multiple mechanisms are thought to be responsible for this myocardial
damage, such as ROS production, apoptosis and mitochondrial dysfunction. Free radical
generation remains the central focus in doxorubicin induced cardiotoxicity.73
Cardiomyocytes are known to not have as effective of an antioxidant protection system
compared to other cell types, and it is well known that ROS production can extremely
alter many organelles in the cell. In vivo studies have shown that enhanced antioxidant
expression greatly reduced doxorubicin induced cardiac toxicity. Another in vivo study
showed that treating mice with doxorubicin led to reduced glutathione peroxidase and
glutathione reductase activity as well as a decrease in GSH level. Doxorubicin also
increased the GSSG level in those mice cardiomyocytes.71
Numerous studies have indicated that antioxidants should be able to block or at
least decrease the cardiotoxicity of doxorubicin without major effect on the antitumor
effect of this drug. The most prominent of the antioxidant protections to date is
dexrazoxane, an iron chelating antioxidant that is FDA approved for prevention of
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doxorubicin-induced cardiotoxicity. Although there are multiple antioxidant agents with a
selective ROS blocking mechanism showing promising results, all of the antioxidant
options have limitations such as toxicity and inconsistency. An in vivo study found that
overexpression of Trx1 in mice protected the heart from damaging reactive oxygen
species.110 Although no studies have been conducted on TXNIP in doxorubicin cardiac
injury, Gao et al found that downregulation of TXNIP protected cells against doxorubicin
kidney injury.103 This indicates that decreasing TXNIP has potential in protection against
doxorubicin-induced toxicity.
Carvedilol is a non-selective antagonist at beta and alpha 1-adrenoceptors. It also
has been observed to possess antioxidant and antiapoptotic effects. Carvedilol is FDA
approved for treatment of hypertension and mild to severe congestive heart failure
(CHF). Multiple studies have shown that carvedilol has effect in prevention of
doxorubicin cardiac toxicity. Carvedilol has been recently used as a prophylactic agent in
patients receiving anthracycline medications. The exact mechanism of carvedilol effect
on doxorubicin-induced cardiotoxicity is not clear.
Previously, we have seen that carvedilol increased the nuclear localization of
TXNIP, the negative regulator of the thioredoxin protein. It concomitantly decreased
cytosolic TXNIP. It was also observed that doxorubicin treatment decreased the level of
TXNIP in the cytosol while increasing its movement into the mitochondria. Because
effects on TXNIP were observed with both agents, we hypothesized that carvedilol may
be able to protect against doxorubicin-induced cardiotoxicity through modulation of
TXNIP localization. Therefore, in the present study, we investigated the potential effect
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of carvedilol on the thioredoxin pathway in cardiomyocyte cells treated with doxorubicin.
In this study, our objectives were:
1. To evaluate the impact of carvedilol on H9c2 cells apoptosis and viability after
exposure to doxorubicin
2. To determine the effect of carvedilol on TXNIP and thioredoxin related
proteins in H9c2 cardiomyocytes treated with doxorubicin
3. To study the effect of doxorubicin on TXNIP complexation with other proteins
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4.2 Materials and Methods
4.2.1 Reagents and Antibodies
Carvedilol and propranolol (Sigma, C3993 and P0884) were dissolved in DMSO
to make 5 mM carvedilol and propranolol stock solutions and were filtered by using a
Medical Millex-GP filter (0.22 µm, sterilized; Millipore). Doxorubicin (Sigma, D1515)
was dissolved in DMSO to make a 0.5 mM stock solution and was filtered using a
Medical Millex-GP filter (0.22 µm, sterilized; Millipore). All stock solutions were stored
at -80°C and were diluted in DMEM medium to the needed concentrations for cell culture
treatment. The final concentration of DMSO in cell culture studies was less than 0.2%.
Trx1 and PARP antibodies were purchased from Cell Signaling Technology
(2298S and 9542); TrxR1 and TXNIP antibodies were obtained from Novus Biologicals,
Inc (NBP2-27095 and NBP2-20619); antibodies to Trx2, TrxR2, Lamin A/C, cytochrome
c, actin, and secondary antibody goat anti-rabbit were purchased from Santa Cruz
Biotechnology (sc-133201, sc-376868, sc-376248, sc-2004 and sc-7210); and the goat
anti-mouse secondary antibody was obtained from Bio-Rad (170-6516).
4.2.2 Cell Culture
H9c2 cells (rat embryonic cardiac myoblasts) were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in Dulbecco’s
modified Eagle’s medium (DMEM, ATCC). DMEM contained 10% (v/v) fetal bovine
serum and 1% (v/v) penicillin/streptomycin, and cells were maintained at 37°C with 5%
CO2. Cells with passage number below 20 were used.
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4.2.3 Cell Viability
H9c2 cells were seeded and treated in 96-well plates, and cell viability was
measured by colorimetric assay containing MTT (3-(4, 5)-dimethylthiazol-2, 5diphenyltetrazolium bromide). H9c2 cells with density of 1,000 cells/well were seeded
and allowed to attach overnight. The cells were treated with doxorubicin (0.01, 0.1, 0.5
and 1.0 µM) and carvedilol (10 µM) or propranolol (10 µM). Cells were treated in
different orders to determine the best protective effect of carvedilol against doxorubicin.
First, a combination of doxorubicin and carvedilol was attempted; cells were treated with
the combination for 24 or 72 hours. Second, cells were pre-treated with carvedilol for 24
hours followed by a treatment with a combination of carvedilol and doxorubicin for an
additional 24 hours. Following drug treatment, the treatment medium was replaced with
regular growth medium, and the cells were allowed to grow for a total of 5 days. MTT
assay was conducted by replacing the medium with medium containing 0.5 mg/ml MTT
solution (50 µl/well) and incubated in the dark at 37°C for at least 4 hours. DMSO (150
µl/well) was added for one hour to dissolve the formed purple formazan product.
SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA, USA) was used
to measure the absorbance of each well by using a test wavelength of 570 nm and a
reference wavelength of 650 nm.
At the end of the MTT assay, we calculated the doxorubicin and carvedilol
combination effect by comparing observed viability to predicted viability. MTT assay
results provided observed cell viability, while the predicted cell viability was calculated
by multiplying the individual treatment effects. Then we subtracted observed viability
from the predicted to decide if the carvedilol and doxorubicin combination treatment was
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additive, antagonistic, or synergistic. This combination will be additive if the net effect is
equal to the product of the individual compounds. It will be antagonistic if the net effect
is less than the individual effects while this combination effect will be synergistic if
carvedilol added to the toxicity of doxorubicin.
4.2.4 Reactive Oxygen Species (ROS) Production
Carboxy-H2DCFDA or C400 (Invitrogen, Life Technologies) was used to
measure ROS production. C400 is a cell-permeable probe, and it will be cleaved by
cellular esterase and oxidized by ROS upon its entry into the cytoplasm which will
produce fluorescence. Briefly, H9c2 cells were seeded in 96 well plates at a density of
20,000 cells/well and allowed to attach overnight. Cells were pretreated with carvedilol
10 µM for 24 hours. The cells then were treated with carboxy-H2DCFDA for 40 minutes
followed by a combination of carvedilol 10 µM and doxorubicin 0.5 µM or 1 µM.
SpectraMax M2 fluorescence microplate reader (Molecular Devices, Sunnyvale,
California) was used to measure the fluorescence intensity at 492 nm excitation and 527
nm emission at different time points ranging from 30 minutes to 4 hours.
4.2.5 Examination of TXNIP, Trx1, TrxR1 and c-PARP Proteins in H9c2 Cells by
Western Blot
TXNIP, Trx1, TrxR1 and c-PARP was determined by using western blot. Two
million H9c2 cells were seeded in 75 cm2 flasks and allowed to attach overnight. The
cells were then pretreated with carvedilol 10 µM for 24 hours followed by a combination
of carvedilol 10 µM and doxorubicin 0.5 µM. Control and doxorubicin flasks were
incubated with medium containing vehicle during the pretreatment period. Then cells
were detached using trypsin and centrifuged at 1000 x g for 5 minutes. The cells were
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separately lysed in lysis buffer containing 20 mM HEPES (pH 7.4), 1% Triton X-100,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 1× broad-spectrum protease inhibitors
(Thermo Fisher Scientific, 88665). Bradford protein assay was used to determine the total
protein concentration, and samples containing 50 µg of protein were separated by 8% or
12% SDS-PAGE followed by transfer onto PVDF membranes. 0.5% bovine serum
albumin (BSA; Sigma, A3294) was used to block the membranes for 3 hours followed by
incubation with primary antibody (1:10,000) overnight. HRP-conjugated secondary
antibody was then added for 1 hour at room temperature. Visualization of the bands was
performed using a kit from GE Biosciences and quantified using a Bio-Rad imaging
system. For this experiment, actin was used as a housekeeping protein.
4.2.6 Isolation of Mitochondrial Fractions from H9c2 Cells
Five million H9c2 cells were seeded in 175 cm2 flasks and allowed to attach
overnight. The cells were then pretreated with carvedilol 10 µM for 24 followed by a
combination of carvedilol 10 µM and 0.5 µM doxorubicin. Control and doxorubicin
flasks were incubated with medium containing vehicle. Then cells were detached by
trypsin and centrifuged at 1000 x g for 5 minutes. A mitochondria isolation kit for
cultured cells (Thermo Fisher Scientific, 89874) was used to isolate the mitochondria.
Western blot was conducted for Trx2, TrxR2, TXNIP, and ASK1 as described above.
Cytochrome c was used to measure the mitochondrial fraction purity. Actin was used as a
housekeeping protein
4.2.7 Cell Fractionation and Nuclear Isolation
Ten million H9c2 cells were seeded in 100-mm petri dishes and allowed to attach
overnight. The cells were then pretreated with carvedilol 10 µM for 24 hours followed
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with a combination of carvedilol 10 µM and doxorubicin 0.5 µM. Control and
doxorubicin flasks were incubated with medium containing vehicle. Then cells were
washed twice with cold phosphate buffered saline (PBS), scraped, and collected with 5
mL of hypotonic buffer [10 mM KCl, 1.5 mM MgCl2, 1 mM sodium orthovanadate, 1 M
Tris and 1x protease inhibitors (Thermo science #88665)]. The cells were centrifuged at
1000 x g for 10 minutes at 4ºC. Then 600 µL of cold hypotonic buffer was used to resuspend the pellet. Exactly 23 strikes on the suspension by a loose fitting Dounce
homogenizer over ice was used to gently separate the cytoplasmic and nuclear fractions.
Then the suspension was centrifuged at 1000 x g for 7 minutes at 4ºC. The supernatant
contained the cytoplasmic fraction while the pellet contained the nuclear fraction. The
pellet was extracted with cold high salt buffer (10 mM Tris-Cl, pH 7.4, 400 mM NaCl,
25% glycerol and 1x protease inhibitors) for 30 minutes at 4ºC and then centrifuged at
20817 x g at 4ºC for 10 min. The supernatant was used for Western blot analysis as
described above. Lamin A/C was used to measure the nuclear fraction purity, and actin
was used as the housekeeping protein.
4.2.8 Immunoprecipitation
Five million H9c2 cells were seeded in 100-mm petri dishes and allowed to attach
overnight. The cells were pretreated with carvedilol 10 µM for 24 hours followed by a
combination of carvedilol 10 µM and doxorubicin 0.5 µM. Control and doxorubicin
flasks were incubated with medium containing vehicle during the pretreatment. Then the
cells were washed with PBS and scraped using lysis buffer. Bradford assay was used for
measuring protein concentrations. 300 µg total protein was immunoprecipitated with
agarose-conjugated anti-Trx2 or anti-PARP antibody in 1 ml of lysis buffer overnight at
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4°C. Then 55 µL of protein G agarose was used to capture the immunocomplexes
followed by incubation for 3 hours at 4ºC. The immunocomplexes were centrifuged at
3000 RPM for 10 minutes, and the pellet was washed three times with lysis buffer. Then
the pellets were collected and suspended in SDS-sample buffer and heated for 10
minutes. Western blot then was performed using anti-TXNIP or anti-ASK1 antibody.
4.2.9 Statistical Analysis
Data are expressed as means ± standard deviation (SD) from three independent
experiments. Statistical analysis was done using ANOVA followed by Tukey’s post hoc
test. A p value of <0.05 was considered to be statistically significant.
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4.3 Results
4.3.1 Cell viability
An MTT assay was conducted to determine cell viability in cells treated with
doxorubicin plus carvedilol. H9c2 cells were treated at the same time with both 10 µM
carvedilol and 0.5 µM doxorubicin for 1 and 3 days. Doxorubicin produced a dose
dependent decrease in cell viability. However, the combination treatment did not yield
any change in cell viability between carvedilol and doxorubicin concentrations at all
concentrations (Figure 25 & Figure 26).
The 24 hour pretreatment of 10 µM carvedilol followed by 0.01, 0.1, 0.5 and 1
µM doxorubicin showed significant viability differences between doxorubicin alone and
the cells with carvedilol treatment. The most significant protection was between 1 µM
doxorubicin treatment and carvedilol (p<0.001) (Figure 27). The antagonistic effect was
calculated to be 48%. Carvedilol pretreatment with 0.1 and 0.5 µM doxorubicin also
showed a statistically significant increase in viability compared to doxorubicin alone. No
statistically significant difference was observed with 0.01 µM doxorubicin (Table 1).
Propranolol, another nonselective beta-blocker, was used as a comparison.
Propranolol did not exhibit any protection against doxorubicin toxicity in H9c2 cells with
combination and with pretreatment respectively (Figure 28 & Figure 29).
4.3.2 Effect of Carvedilol Pretreatment on Doxorubicin-Induced ROS Production
Studies have shown that doxorubicin is able to produce ROS in a dose and time
dependent manner. To determine whether carvedilol pretreatment can reduce ROS
production or not, cells were pretreated with carvedilol for 24 hours followed with
combination treatment. Doxorubicin 0.5 µM did not induce a statistically significant
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increase in ROS. However, doxorubicin 1 µM showed a statistically significant increase
in ROS which was reduced by treatment with carvedilol (Figure 30). ROS production
was detected in 0.5 µM in 12 and 24 hours and carvedilol was able to reverse it (Figure
31). While with no carvedilol pretreatment in 12 and 24 hours the carvedilol was not able
to reverse doxorubicin ROS production (Figure 32).
4.3.3 Carvedilol and Doxorubicin Combination Impact on Major Thioredoxin
Proteins: Trx1, TrxR1, Trx2, TrxR2 and TXNIP
The protein level of TXNIP, Trx1, and TrxR1 was determined in the cytosol
following pretreatment with carvedilol 10 µM for 24 hours followed by combination of
10 µM carvedilol and 0.5 µM doxorubicin. The mitochondrial isoforms Trx2 and TrxR2
were evaluated in the mitochondria after the same treatment. The cytosolic level of
TXNIP decreased significantly with carvedilol (40%) and doxorubicin (50%)
individually. TXNIP decreased even further with a combination treatment of carvedilol
and doxorubicin compared to control (70%) (Figure 33). Protein expression for Trx1
(Figure 36), TrxR1 (Figure 37), Trx2 (Figure 38), and TrxR2 (Figure 39) was not
statistically significantly different from control at 24 hours for any treatments.
4.3.4 Impact of Carvedilol on TXNIP Localization in Nucleus and Mitochondria
TXNIP is known to shuttle between the nucleus, cytosol, and mitochondria. Here,
we determined the TXNIP levels in subcellular fractions in cells treated with a
combination of carvedilol and doxorubicin. Carvedilol increased TXNIP localization in
the nucleus as expected. However, there was no statistically significant difference in
TXNIP level for doxorubicin or the combination treatment compared to control in the
nuclear fraction (Figure 34). Doxorubicin alone significantly increased TXNIP in the
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mitochondria. Carvedilol treatment did not change the accumulation of TXNIP in the
mitochondria caused by doxorubicin (Figure 35).
4.3.5 Carvedilol and Doxorubicin Combination Impact on PARP, cleaved PARP
and ASK1 Level
The protein levels of PARP, cleaved PARP, and ASK1 were determined after
pretreatment with carvedilol 10 µM for 24 hours followed with a combination of
carvedilol 10 µM and doxorubicin 0.5 µM. Carvedilol had no effect on PARP or cleaved
PARP. Doxorubicin exhibited a significant increase in cleaved PARP, which is consistent
with induction of apoptosis. Carvedilol partially blocked the increase in cleaved PARP
indicating that carvedilol exhibited protection against doxorubicin-induced apoptosis
(Figure 40) The ASK1 expression did not change with this treatment (Figure 41)
4.3.6 Effect of carvedilol on Trx1-ASK1 and TXNIP-PARP Protein Complexation
TXNIP is known to shuttle to the mitochondria under oxidative stress conditions
and bind to Trx2, releasing ASK1 protein leading to apoptosis.111 We performed
immunoprecipitation in mitochondrial extracts to measure the Trx2-ASK1 complexation
after carvedilol and doxorubicin treatment. Following immunoprecipitation with antiTrx2 antibody, Western blot was performed with ASK1 antibody. This complex
expression was slightly higher in carvedilol compared to control, and as expected
doxorubicin decreased this complexation while the pretreatment with carvedilol reversed
doxorubicin’s effect (Figure 42). As described in chapter 2, carvedilol was able to
increase the TXNIP-PARP complexation in the nucleus. The same observation was seen
with carvedilol, while doxorubicin and the combination treatment showed the same level
as control (Figure 43)
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Figure 25. Cell viability assay in H9c2 cells treated with a combination of 10 µM
carvedilol and 0.5 µM doxorubicin for 3 days.
This assay statistics are shown as percentage of control and expressed as the means ± SD
of 3 different experiments. One-way ANOVA followed by Tukey’s post hoc test were
performed to analyze data.
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Table 1. H9c2 cells treated with a combination of 10 µM carvedilol and 0.5 µM
doxorubicin for 3 days.

Treatment

Predicted Cell
Viability (%)

Observed Cell
Viability (%)

Effect (%)

0.01µM Dox + 10µM
Carvedilol

80

77

3

0.1µM Dox + 10µM
Carvedilol

70

62

8

0.5µM Dox + 10µM
Carvedilol

52

48

4

1.0µM Dox + 10µM
Carvedilol

26

21

5
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Figure 26. Cell viability assay in H9c2 cells treated with a combination of 10 µM
carvedilol and 0.5 µM doxorubicin for 24 hours.
This assay statistics are shown as percentage of control and expressed as the means ± SD
of 3 different experiments. One-way ANOVA followed by Tukey’s post hoc test were
performed to analyze data.

80
Table 2. H9c2 cells treated with a combination of 10 µM carvedilol and 0.5 µM
doxorubicin for 24 hours.

Treatment

Predicted Cell
Viability (%)

Observed Cell
Viability (%)

Effect (%)

0.01µM Dox + 10µM
Carvedilol

89

87

2

0.1µM Dox + 10µM
Carvedilol

78

73

5

0.5µM Dox + 10µM
Carvedilol

52

49

2

1.0µM Dox + 10µM
Carvedilol

31

28

3
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Figure 27. Cell viability assay in H9c2 cells treated with 10 µM carvedilol pretreatment
for 24 hours followed by treatment with carvedilol and 0.5 µM doxorubicin for 24 hours.
This assay statistics are shown as percentage of control and expressed as the means ± SD
of 3 different experiments. One-way ANOVA followed by Tukey’s post hoc test were
performed to analyze data. ** p < 0.01 and *** p < 0.001 compared with control group.
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Table 3. H9c2 cells treated with 10 µM carvedilol pretreatment for 24 hours followed by
treatment with carvedilol and 0.5 µM doxorubicin for 24 hours.

Treatment

Predicted Cell
Viability (%)

Observed Cell
Viability (%)

Effect (%)

10µM Carvedilol /0.01µM
Dox + 10µM Carvedilol

84

94

10

10µM Carvedilol /0.1 µM
Dox + 10µM Carvedilol

71

92

21

10µM Carvedilol /0.5 µM
Dox + 10µM Carvedilol

56

87

31

10µM Carvedilol 1.0 µM
Dox + 10µM Carvedilol

27

75

48
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Figure 28. Cell viability assay in H9c2 cells treated with a combination of 10 µM
propranolol and 0.5 µM doxorubicin for 3 days.
This assay statistics are shown as percentage of control and expressed as the means ± SD
of 3 different experiments. One-way ANOVA followed by Tukey’s post hoc test were
performed to analyze data.
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Figure 29. Cell viability assay in H9c2 cells treated with 10 µM propranolol pretreatment
for 24 hours followed by treatment with propranolol and 0.5 µM doxorubicin for 24
hours.
This assay statistics are shown as percentage of control and expressed as the means ± SD
of 3 different experiments. One-way ANOVA followed by Tukey’s post hoc test were
performed to analyze data.
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Figure 30. ROS production in H9c2 cells with pretreatment of carvedilol followed by
treatment with carvedilol and doxorubicin for short time periods (30 minutes-4 hours).
The data are presented as fluorescence intensity and expressed as the means ± SD of
three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. ** p < 0.01 and *** p < 0.001
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Figure 31. ROS production in H9c2 cells pretreatment with carvedilol followed by
treatment with carvedilol and doxorubicin for 12 and 24 hours.
The data are presented as fluorescence intensity and expressed as the means ± SD of
three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. ** p < 0.01 and *** p < 0.001
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Figure 32. ROS production in H9c2 cells treated with a combination of carvedilol and
doxorubicin for 12 and 24 hours.
The data are presented as fluorescence intensity and expressed as the means ± SD of
three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point.
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Figure 33. Effect of 10 µM carvedilol and 0.5 µM doxorubicin treatments on cytoplasmic
TXNIP expression in H9c2 cells after 24 hour treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. ** p < 0.01 and *** p < 0.001 compared
with control group.
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Figure 34. Effect of 10 µM carvedilol and 0.5 µM doxorubicin treatments on nuclear
TXNIP expression in H9c2 cells after 24 hour treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. * p < 0.05 compared with control group.
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Figure 35. Effect of 10 µM carvedilol and 0.5 µM doxorubicin treatments on
mitochondrial TXNIP expression in H9c2 cells after 24 hour treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. ** p < 0.01 and compared with control
group.
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Figure 36. Effect of 10 µM carvedilol and 0.5 µM doxorubicin treatments on Trx1
expression in H9c2 cells after 24 hour treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point.
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Figure 37. Effect of 10 µM carvedilol and 0.5 µM doxorubicin treatments on TrxR1
expression in H9c2 cells after 24 hour treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point.
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Figure 38. Effect of 10 µM carvedilol and 0.5 µM doxorubicin treatments on Trx2
expression in H9c2 cells after 24 hour treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point.
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Figure 39. Effect of 10 µM carvedilol and 0.5 µM doxorubicin treatments on TrxR2
expression in H9c2 cells after 24 hour treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point.
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Figure 40. Effect of 10 µM carvedilol and 0.5 µM doxorubicin treatments on PARP and
cleaved PARP expression in H9c2 cells after 24 hour treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time point. * p < 0.05
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Figure 41. Effect of 10 µM carvedilol and 0.5 µM doxorubicin treatments on ASK1
expression in H9c2 cells after 24 hour treatment.
The data are presented as relative intensity (protein/actin) and expressed as the means ±
SD of three independent experiments. One-way ANOVA and Tukey’s post hoc test were
performed to analyze data at each time poin
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Figure 42. Anti-ASK1 antibody immunoblots of 10 µM carvedilol and 0.5 µM
doxorubicin treatments immunoprecipitated with anti-Trx2 antibody.
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Figure 43. Anti-TXNIP antibody immunoblots of 10 µM carvedilol and 0.5 µM
doxorubicin treatments immunoprecipitated with anti-PARP antibody.
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4.4 Discussion
Doxorubicin-induced cardiotoxicity is believed to be mediated through the
induction of oxidative stress. Carvedilol is unique among the beta-blockers as it has been
shown to protect cardiomyocytes against oxidative stress. Multiple mechanisms have
been suggested for carvedilol’s protection such as free radical scavenging, suppressing
the enzymatic generation of reactive oxygen species, and reduction of apoptotic and
inflammation markers. However, there is limited information in the literature about the
role of the thioredoxin pathway in carvedilol’s antioxidant activity. In chapter 2, it was
demonstrated that carvedilol was able to reduce TXNIP expression in the cytosol while
increasing localization in the nucleus. This was accompanied by a change in TXNIP
complexation with major proteins such as Trx1 and PARP. Chapter 3 showed the ability
of doxorubicin to reduce cytoplasmic TXNIP expression. A previous literature report
indicated that TXNIP downregulation was effective in reducing kidney injury induced by
doxorubicin. Therefore, we investigated in this chapter the effect of carvedilol and
doxorubicin treatment on TXNIP and related proteins in H9c2 rat cardiomyocytes. Our
focus was to understand the involvement of the thioredoxin system in carvedilol
cardioprotection and its impact on doxorubicin induced cardiotoxicity.
MTT assays were initially performed to test the possible cardioprotective effects
of carvedilol. H9c2 cardiomyocyte cells were treated with carvedilol and doxorubicin at
different times, orders, and concentrations. The best protective effect was shown when
H9c2 cells were pretreated with carvedilol for 24 hours followed by treatment with
carvedilol and doxorubicin for another 24 hours. Carvedilol exhibited significant
antagonistic effects against doxorubicin with this regimen, and the greatest protection
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was detected with the highest dose of doxorubicin (1µM). Other treatment regimens did
not demonstrate any carvedilol protection against doxorubicin cardiac toxicity.
Significantly, this indicates that pretreatment with carvedilol was required for the
cardioprotection.
Carvedilol is well known in the literature for its antioxidant activity and its ability
in bind and scavenge ROS in the body. On the other hand, increasing levels of
mitochondrial reactive oxygen species are required for doxorubicin cardiac toxicity.112
Our observation of increasing TXNIP in the mitochondria with doxorubicin treatment
lines up with the literature. As a result, ROS production in H9c2 cells treated with
carvedilol and doxorubicin was also determined. The results showed that 0.5 µM
doxorubicin treatment showed a significant increase in ROS production with 12 and 24
hour treatments. Shorter treatment times did not show significant ROS production with
0.5 µM doxorubicin. However, 1 µM doxorubicin did induce ROS production at short
time points. This indicates that doxorubicin ROS production is time and dose dependent.
As expected, 10 µM carvedilol pretreatment was able to reduce the production of ROS
induced by doxorubicin. However, this effect was only observed with carvedilol
pretreatment. No benefit was found with combination treatment. This again confirms the
necessity of carvedilol pretreatment and indicates that intracellular changes occurring
within the 24 hour pretreatment are required for carvedilol’s protection.
Next, the combination effect of carvedilol and doxorubicin on the thioredoxin
system in H9c2 cells was evaluated to understand the role of this system in carvedilol
cardiac protection against oxidative stress. We have already observed that doxorubicin
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alone decreased TXNIP in the cytoplasm. Instead, TXNIP was found to be translocated to
the mitochondria; this is consistent with induction of oxidative stress. Carvedilol alone
initiated translocation of TXNIP to the nucleus. However, combination treatment of
carvedilol and doxorubicin did not show accumulation of TXNIP in the nuclear fraction.
Opposite to what we expected, carvedilol did not reverse TXNIP accumulation in the
mitochondria with doxorubicin treatment as we observed the same level of TXNIP in the
mitochondria with the combination treatment as doxorubicin alone. Furthermore, this
combination treatment did not affect any other related proteins in this system.
TXNIP in the mitochondria can form a complex with Trx2. Formation of this
complex is believed to release ASK1 leading to induction of apoptosis. Based on this, the
TXNIP accumulation in the mitochondria would be expected to lead to reduced formation
of the Trx2-ASK1 complex. This expected result was observed with doxorubicin
treatment alone. However, carvedilol pretreatment did not exhibit decreased Trx2-ASK1
complexation compared to control. TXNIP complexation with PARP in the nucleus was
also investigated. The TXNIP-PARP complexes seen with carvedilol alone were
decreased in the combination treatment. This also support the translocation of TXNIP out
of the nucleus to the mitochondria. On other hand, doxorubicin was able to increase
cleaved PARP, a proapoptotic protein, indicating that doxorubicin is causing apoptosis in
H9c2 cells. Carvedilol pretreatment was able to significantly reverse this effect. This
observation is consistent with the increase in Trx2-ASK1 complex in the mitochondria
indicating antiapoptotic effect.
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The interaction between Trx and ASK1 involves a redox sensitive disulfide bond.
The complex formation has been studied in detail between the cytosolic Trx1 and ASK1.
The disulfide bond forms between cysteine-32 of Trx1 and cysteine-250 of ASK1. Upon
oxidative stress, an intramolecular disulfide bond between cysteine-32 and cysteine-35 of
Trx1 forms thereby releasing ASK1 from the complex. Then, ASK1 undergoes
intramolecular disulfide bond formation leading to its activation and induction of
apoptosis.111 Under oxidative stress, TXNIP can translocate to the mitochondria where it
can also form a disulfide bond with Trx. Under conditions of mild oxidative stress, a
disulfide bond between cysteine-32 of Trx and cysteine-247 of TXNIP forms. This is
often associated with increased activity of ASK1 leading to apoptosis. However, there is
also evidence that the formation of the Trx-TXNIP complex can alter the transcription of
other antioxidant proteins such as SOD and catalase. Therefore, the translocation of
TXNIP to the mitochondria under mild oxidative stress will not necessarily induce
apoptosis and can actually promote cell survival through enhanced anti-oxidant capacity.
The situation changes with more severe oxidative stress. In this case, the complex
between Trx and TXNIP is broken in favor of intramolecular disulfide bonds. The free
TXNIP in the mitochondria initiates formation of a complex known as the NLRP3
inflammasome. The release of ASK1 and the formation of the inflammasome both
contribute to oxidative stress-induced apoptosis.64
In this study, doxorubicin significantly increased ROS production. This induction
of oxidative stress promoted the translocation of TXNIP to the mitochondria and the
induction of apoptosis, as expected. Carvedilol alone moved TXNIP into the nucleus.
However, in the combination, the TXNIP was translocated out of the nucleus and to the
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mitochondria. However, this did not lead to induction of apoptosis; in fact, apoptosis
markers were significantly decreased. This may be explained by the different responses
to oxidative stress described above. Carvedilol significantly reduced the ROS produced
by doxorubicin; however, the ROS level was still above that of control. This ROS
production could be significant enough to cause the translocation of TXNIP to the
mitochondria. In doxorubicin treated cells, the accumulation of TXNIP in the
mitochondria was associated with apoptosis induction similar to what is observed with
high levels of oxidative stress. The combination treatment exhibited an effect comparable
to mild oxidative stress conditions with increased complexation of TXNIP-ASK1 and
reduced cleaved PARP. This may be associated with induction of other antioxidant
enzymes. This would be consistent with the observation that pretreatment with carvedilol
was required for the improvement in cell viability and the reduction in ROS. If direct free
radical scavenging was the primary mechanism, it would have been expected to see these
effects without pretreatment. However, since the pretreatment was required, it is logical
to consider that induction of antioxidant proteins by carvedilol is responsible for
protective effect, similar to that observed with mild oxidative stress. Further study is
needed to confirm the upregulation of antioxidant proteins. In addition, complexation of
Trx2 and ASK1 in the mitochondria should be examined to verify the mild oxidative
stress response.
In conclusion, carvedilol was able to protect against apoptosis and oxidative stress
induced by doxorubicin. This effect required carvedilol pretreatment. It was accompanied
by increased Trx2-ASK1 complexation in the presence of TXNIP in the mitochondria.
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The observed data was consistent with that previously reported for a mild oxidative stress
response.
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CHAPTER 5. CONCLUSIONS
This dissertation presents the impact of carvedilol treatment on the thioredoxin
system as well as the role of carvedilol and TXNIP in protecting H9c2 cells against
oxidative stress produced by doxorubicin. In this study, carvedilol was found to be able to
induce translocation of TXNIP, the negative regulator of Trx, to the nucleus. This
compartmentalization of TXNIP from the cytoplasm to the nucleus was associated with
an increase in TXNIP-PARP complexation in the nuclear fraction and a decrease in
TXNIP-Trx1 complexation in the cytosol (figure 44).

Figure 44. Effect of carvedilol in TXNIP localization under normal conditions.
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Glucose levels have been found to change TXNIP expression in the cytosol.
Cytosolic TXNIP increased with increasing glucose concentration in the H9c2 cells. This
observation is consistent with the literature.113 Furthermore, TXNIP expression was
decreased with different oxidative stress inducers. Doxorubicin and hypoxiareoxygenation significantly decreased TXNIP expression. Both of those two methods
generate ROS which suggests that TXNIP was moved to the mitochondria under those
conditions. These findings suggest that modulating TXNIP translocation in the cell may
be a potential target in diabetic cardiomyopathy and doxorubicin cardiac toxicity.
Doxorubicin increased ROS production after 12 and 24 hours of treatment at the
0.5 µM concentration while the higher dose increased it at shorter time points. That
proves that doxorubicin cardiotoxicity is time and dose dependent. Carvedilol was able to
protect cardiomyocytes from doxorubicin toxicity. However, only cells pretreated with
carvedilol were protected from toxicity from the doxorubicin treatment. This finding is
supported by literature showing that pretreatment of carvedilol protected against
doxorubicin damage in adult B6 mice.114 This is also consistent with our finding that
carvedilol was able to prevent doxorubicin ROS production only in pretreated cells. The
requirement for pretreatment indicates that a change in expression of endogenous
antioxidant proteins may be involved in carvedilol’s antioxidant effect. In fact, previous
literature has shown that carvedilol plus doxorubicin resulted in an increase in expression
and activity of other antioxidant proteins such as SOD and catalase.115 Further study
should be conducted to determine the effect of carvedilol plus doxorubicin on expression
of antioxidant proteins under the conditions used in this study.
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Carvedilol and doxorubicin did not affect expression of any other protein in the
thioredoxin family besides TXNIP. Doxorubicin translocated TXNIP to the mitochondria
and decreased Trx2 complexation to ASK1, while carvedilol increased translocation to
the nucleus. The combination caused a further reduction in cytosolic TXNIP, but
carvedilol pretreatment did not prevent TXNIP translocation to the mitochondria.
However, this was associated with restored Trx2-ASK1 complexation and reduced
apoptosis. This finding is consistent with mild oxidative stress. In order to study this
further, the complex of Trx1 and TXNIP in the cytosol and Trx2 and TXNIP in the
mitochondria should be evaluated.
This study was conducted in the H9c2 rat cardiomyocytes model, and the main
limitation of this model is that it is a non-contractile model. Thus, study in either an in
vivo system or an ex vivo contractile system is needed to truly measure the effect of
carvedilol treatment on the thioredoxin system and its role in protecting against
doxorubicin toxicity. Another major limitation of this study is that it was difficult to
determine the exact impact of TXNIP with the model used. In order to further study the
role of TXNIP in cardioprotection by carvedilol, a TXNIP knockout mouse model or
silencing the gene in a cell culture would be ideal. In addition, the mechanisms behind
TXNIP movement within the cell are unclear. Importin alpha has been shown to be
required for entry into the nucleus. However, export from the nucleus is not well
understood. Also, the mechanisms for movement to the mitochondria are still unclear.
Identifying these mechanisms of TXNIP movement to the mitochondria would be
beneficial in finding a blocker to reduce doxorubicin toxicity.
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Carvedilol is a non-selective β-adrenoceptor blocker and is used in the treatment
of heart failure and hypertension. Unlike other β blocking drugs, carvedilol uniquely
possesses antioxidant activity.65, 66 In this study, carvedilol was able to translocate TXNIP
to the nucleus while propranolol, atenolol and metoprolol did possess this effect.
Carvedilol pretreatment protected H9c2 cells from doxorubicin toxicity while propranolol
failed in that. These results suggest that carvedilol has unique off-target effects that
should be further investigated for clinical significance. The previous literature has shown
the ability of other agents such as verapamil, ramipril, and insulin to reduce TXNIP
mRNA expression or degradation. Interestingly, carvedilol’s effect on TXNIP is unique
from these agents. Carvedilol does not decrease the overall TXNIP pool while verapamil,
ramipril, and insulin actually decrease total cellular TXNIP. It is unclear which of these
approaches would be most advantageous. Since TXNIP is a tumor suppressor gene,
decreasing its expression could have a negative impact on cell growth. Therefore,
carvedilol’s mechanism might make it safer to use without increasing the risk of
carcinogenesis. On the other hand, as was observed in this study, the TXNIP is still
capable of moving within the cell with carvedilol treatment while this effect might be
reduced with agents that decrease transcription or increase degradation of TXNIIP; this
could limit carvedilol’s impact compared to other approaches. However, in this study, no
negative impact of TXNIP translocation to the mitochondria with doxorubicin and
carvedilol was observed.
In conclusion, this study shows for the first time that carvedilol impacts TXNIP
localization and complexation and that the thioredoxin pathway may be involved in
carvedilol’s observed cardioprotective effect. Carvedilol succeeded in protecting against
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doxorubicin toxicity through decreases activation of cell apoptotic signaling and
reduction of oxidative stress. Carvedilol is currently used for the treatment of heart failure
and hypertension. Multiple reports have shown its ability to work as an antioxidant,
though the exact mechanism of antioxidant activity is not known. This dissertation study
reported its ability to modulate the cardiac cells’ antioxidants activity through modulating
the TXNIP protein. This mechanism might explain carvedilol’s antioxidant activity and
how it contributes to cardioprotection. This knowledge may also lead to expanded
therapeutic uses of carvedilol such as in other cardiovascular diseases, diabetes, and
diabetes complications.
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